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Background: While incidence rates of tuberculosis (TB) are on the decline globally, the 
TB burden in sub-Saharan Africa and Southeast Asia remains high.  If the goal of 
reducing the global TB incidence rate to < 10/100,000 population per year is to be 
achieved by 2035, additional TB control interventions will need to be deployed in high 
burden settings.  Research is needed to identify effective, efficient interventions that 
prevent additional TB cases, identify and properly diagnose incident cases, as well as to 
provide timely, appropriate treatment and ensure treatment completion.  We sought to 
evaluate several TB control interventions as implemented in local contexts, including a 
household contact tracing in rural South Africa, a cost-effectiveness analysis of 
interferon-γ release assays (IGRAs) in India, and predictors of isoniazid preventive 
therapy (IPT) completion in rural Malawi.  This research aims to provide data for policy-
makers and government officials tasked with the deployment of scarce TB control 
resources in local contexts, with the goal of identifying strategies to integrate TB case 
finding and prevention activities into programs with limited resources.  
Methods: We recruited 130 newly diagnosed TB patients (“index cases”) from public 
clinics in Vhembe District, Limpopo Province, South Africa, and visited their homes to 
test their household contacts for TB via sputum smear microscopy and culture.  Clinical 
and demographic characteristics, including HIV status, were assessed via self-report.  
We calculated the yield of previously undiagnosed TB disease among household 
contacts (defined as the number of new TB cases identified for every 100 index cases 
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traced) and evaluated risk factors for TB disease among household contacts using 
multilevel logistic regression.   
Next we evaluated the incremental cost-effectiveness of IGRAs compared to a base-case 
scenario of empirical diagnosis (without microbiological testing), as well as sputum 
smear microscopy and Xpert MTB/RIF.  We performed our analysis from the perspective 
of the Indian TB Control Program, and evaluated the cost, disability-adjusted life years, 
deaths, and secondary cases averted, and false positive diagnoses resulting from the use 
of these diagnostics in a hypothetical cohort of 1 million adult Indian TB suspects.  We 
performed one-way sensitivity analyses, as well as a probabilistic sensitivity analysis to 
generate uncertainty ranges around our estimates.   
Finally we evaluated factors associated with IPT completion in a cohort of 974 newly 
diagnosed adult HIV patients in Malawi who were started on IPT after active TB disease 
was excluded.  Participants were recruited as part of a larger cluster randomized trial of 
TB screening being conducted in 12 clinics across rural Malawi.  IPT completion was 
defined as receipt of ≥150 doses of isoniazid during routine clinical visits.  We assessed 
factors associated with IPT completion using a multilevel logistic regression model 
adjusted for patient clinical and demographic characteristics.   
Results:  A total of 282 household contacts were enrolled in our household contact 
tracing study between December 1, 2013 and September 30, 2014.  A total of 11 
individuals tested positive for TB disease, for a household TB disease prevalence of 3.9% 
(95% CI: 2.0-6.9%) and a yield of 8.5 cases per 100 index cases traced (95% CI: 4.2-15.1).  
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The majority of TB cases identified by the study (10/11, 90.9%) were smear-
negative/culture-positive.  The presence of TB symptoms was not significantly 
associated with increased odds of active TB disease in our population (aOR: 0.3, 95% CI: 
0.1-1.4).   
 
Our cost-effectiveness analysis found that IGRAs were less cost-effective than sputum 
smear microscopy or Xpert MTB/RIF when diagnosing active TB in India.  This was largely 
due to the poor specificity of IGRAs for active TB in a setting with high background rates 
of latent TB infection.  Relative to sputum smear microscopy, IGRAs resulted in 315,700 
(95% uncertainty range [UR]: 118,300 – 388,400) false-positive TB diagnoses, at an 
incremental cost of US$49.3 million (95% UR: $34.9 - $58.0 million) per 1 million 
population tested.  Relative to Xpert MTB/RIF (including the cost of treating drug 
resistant TB), IGRAs averted 70,400 (95% UR: [-7,900] – 247,200) fewer disability 
adjusted life years and cost US$14.6 million (95% UR: [-$7.2] - $28.7 million) more.  
 
In Malawi, 732 of the 974 (75%) individuals who started IPT completed their course of 
therapy.  Individuals completing IPT were significantly older than non-completers (34 vs. 
31, p<0.01) and less likely to have experienced an interruption of >2 months (7.1% vs. 
80%, p=0.01).  After controlling for potential confounders, participants younger than 25 
years (compared to those over 45 years, aOR: 0.33, 95% CI: 0.18-0.60) and males 
(compared to non-pregnant women, aOR: 0.57, 95% CI: 0.37-0.88) had significantly 
lower odds of IPT completion.  Concomitant receipt of ART drugs, being a current or 
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former smoker, and self-reported alcohol use were not significantly associated with IPT 
completion in our study. 
Discussion: Identification of effective and cost-effective interventions operationalizing 
case finding and prevention of TB will be vital in controlling TB and meeting ambitious 
global targets by 2035, especially in high-burden settings.  We evaluated potential 
prevention and case-finding interventions in local settings, providing data useful to TB 
control programs and governments in sub-Saharan Africa and Southeast Asia, where 
high TB burdens and scarce resources present substantial challenges to meeting global 
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Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB), infects 
approximately a third of the global population [1,2].  M. tuberculosis is transmitted 
through the air via droplets when an infectious individual talks, sings [3], or coughs [4,5].  
Tuberculosis infections can be classified as either “latent” (non-transmissible TB 
infection) or “active” (generally symptomatic, transmissible TB disease).  While those 
with latent TB infections are asymptomatic and non-infectious [6,7], approximately 5-
15% of these individuals will progress to active disease over the course of their lifetimes 
[8].  Active TB disease most often affects the lungs (known as “Pulmonary TB”), causing 
a constellation of symptoms including cough, fever, night sweats, weight loss, and 
lethargy.  Extra-pulmonary TB can also occur, and may effect a range of body systems 
[9].  Untreated, up to two-thirds of those with active TB disease will die [10].  On 
average, infectious individuals will transmit TB to between 10-15 susceptible individuals 
over the course of a year [11], though evidence suggests that so-called “super-
spreaders” can infect many more [12,13]. 
Close contact with an individual suffering from untreated, pulmonary TB is the 
predominant risk factor for infection with M. tuberculosis.  As many as half of the 
household contacts of an infectious TB case will themselves become latently infected, 
especially if the infectious case has smear positive TB disease [8].  A number of agent, 
host, and environmental factors are associated with progression from latent infection to 
active TB disease.  These include recent infection with TB, being less than 5 years old 
[14], being homeless [15], living/working in a congregate setting such as hospitals [16–
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18] or prisons [19,20], smoking [21], alcohol [22] and substance abuse [23], diabetes 
[24], end stage renal disease [25], low body weight [26], and a number of other 
conditions that weaken the immune system [27–29].   
Most notably, human immunodeficiency virus (HIV) infection increases the risk 
of TB disease by an estimated 29 times [23,30].  Globally TB remains the leading cause 
of death among people living with HIV (PLHIV), a third of whom are infected with latent 
TB and at high risk of progression to active TB disease.  This dual epidemic has been 
most pronounced in sub-Saharan Africa, home to nearly 80% of TB/HIV co-infected 
individuals worldwide and 9 of the 22 countries classified as “high-burden” for TB by the 
World Health Organization (WHO) [31].  In countries such as South Africa, high HIV 
prevalence rates have led to a more than 3-fold increase in the number of TB case-
notifications since 1990, and annual TB incidence rates peaked as high as 1,000 per 
100,000 per population in 2012 [32].  This has led to large-scale morbidity and mortality, 
and has strained already fragile healthcare systems in South Africa and other high 
TB/HIV burden countries.   
While annual TB incidence rates per population are highest in South Africa and 
neighboring Swaziland and Lesotho, globally India contributes the largest number of 
incident cases each year.  In 2013 India had an estimated 2.0-2.3 million incident TB 
cases; approximately 2.2% (1.9-2.6%) of new TB cases had multi-drug resistant (MDR) 
TB, and 15% (11-19%) of retreatment cases were diagnosed as having MDR-TB [33].  
Unlike South Africa, however, the TB epidemic in India is not driven primarily by HIV 
infection.  Just over 5% of the incident TB cases in 2013 were estimated to have been 
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HIV-infected in India, compared to about 60% of all TB cases in South Africa [34].  
Despite these differences, in both India and South Africa (as well as other low- or 
middle-income countries) TB control is hindered by a number of factors including 
resource constraints, large rural populations, and limited healthcare infrastructure.   
 
Global TB Control 
 An estimated 9 million incident cases of TB occurred globally in 2013, for an 
average worldwide TB incidence rate of 126 cases per 100,000 population [31].  Just 
over a million of these cases were thought to have been co-infected with HIV.  While 
annual TB incidence continues to decline slowly worldwide, the vast majority of new 
cases still occur in the WHO Africa Region (29% of all new cases) and Asia (56% of all 
new cases) [31].  Incident rates in the Africa Region have fallen far more slowly than 
global averages, likely because of the HIV co-epidemic in that region.  While global TB 
incidence rates have fallen from nearly 150 per 100,000 in 2002 to approximately 125 
per 100,000 in 2011, TB incidence rates in the WHO Africa Region generally, and in 
South Africa specifically, remain far higher, at 275 and 993 per 100,000 population, 
respectively [31].  Consistently high rates of TB in this region can be attributed in part to 
population growth and accelerating urbanization, poverty, inadequate health 
infrastructure, insufficient case-detection rates, and the high prevalence of HIV/AIDS 
[35].  Given these challenges (and despite slow global reductions in both TB incidence 
and prevalence) it does not appear that the 2015 Millennium Development Goal (MDG) 
target of a 50% reduction in the TB prevalence from 1990-2015 will be met worldwide.   
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Though the 2015 goals were not met, there has been substantial progress 
worldwide in controlling TB, and the WHO has set ambitious post-2015 targets as a part 
of their “End TB Strategy”.  This strategy include a goal of ending TB by 2035 (defined as 
a 95% reduction in the number of annual TB deaths from 2015-2035 and a global TB 
incidence rate of less than 10/100,000 population per year) [36].  The first pillar of this 
strategy comprises a focus on “integrated, patient-centered care and prevention” of TB, 
including “early diagnosis of tuberculosis…and systematic screening of contacts and 
high-risk groups” as well as “preventive treatment of persons at high risk” of TB disease 
[36].  The strategy also recognizes the need for research into the potential impacts and 
optimal implementation of prospective interventions.   
Given that 85% of all incident cases of TB continue to occur in the Asian and 
African Regions, identifying efficient, cost-effective interventions adapted to local 
contexts is particularly important if ambitious global TB targets are to be met.  However, 
in these settings inadequate health infrastructure and limited resources often present 
further challenges to TB control, especially in rural areas.  Epidemiological data, as well 
as implementation science and operational research, are crucial to the development 
and evaluation of potential interventions for TB control under real-world conditions.   
Potential interventions may be designed to address different aspects of the TB 
prevention and case finding pathway; to prevent TB disease in high-risk individuals, to 
find a greater proportion of all TB cases (and to diagnose them earlier in the disease 
course), to effectively screen and treat those at highest risk for active disease, and to 
ensure that those on preventive or curative treatment complete their course of 
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medication (Figure 1.1).  Interventions at each phase of this prevention, diagnosis, and 
treatment pathway need to be evaluated rigorously under operational conditions to 
ensure the efficient deployment of scare TB control resources, especially in rural 
settings, where resource and infrastructure constraints may complicate 
implementation. 
We sought to evaluate interventions implemented in rural high-burden areas 
targeting points along the TB case-finding and prevention pathway (Figure 1.1); 
specifically 1) Active case-finding to identify and screen individuals at high risk for TB 
disease, 2) Evaluation of the incremental cost-effectiveness of diagnostic tests for active 
pulmonary TB, and 3) Identification of predictors for isoniazid preventive therapy (IPT) 
completion among adults newly diagnosed with HIV.  While each of these analyses 
focuses on a different point on the pathway, together the interventions evaluated work 
to prevent TB disease and correctly identify additional TB cases under real-world 
conditions in low-resource settings.  Ultimately the widespread implementation of such 
evidence-based, cost-effective interventions for TB control is needed to reduce the 




 Timely diagnosis and prompt treatment initiation have been linked to reductions 
in TB-related morbidity and mortality.  However, in low-resource, high-burden settings, 
TB case-finding typically consists of passive case detection methods, strategies which 
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rely on symptomatic individuals self-presenting at health facilities [37].  Self-
presentation is frequently delayed by barriers including distance to health facilities, 
poverty, lack of education or awareness of TB, and other competing needs (e.g. school, 
work) [38,39].  These barriers may be of even greater concern in rural areas where 
health facilities are more sparsely located and transport options are more limited in 
comparison to urban/peri-urban areas.  As a result of such barriers, estimates suggest 
that individuals with active pulmonary TB may go more than a year between symptom 
onset and diagnosis (or death) [40].  These diagnostic delays lead to increased morbidity 
and mortality, further secondary disease transmission, higher costs to healthcare 
systems, and inadequate case-detection rates [41–43].  As a result, passive case-
detection alone has not been adequate to control epidemics of TB, especially in settings 
with high rates of HIV [44].   
 Strategies to boost TB case-finding rates above and beyond that of passive case-
detection alone have been developed.  Generally these strategies fall into one of two 
categories; Enhanced case-finding (ECF) or active case-finding (ACF).  Like passive case-
detection, ECF methods are still patient-initiated, but include educational or 
informational campaigns by the health system to inform communities of TB, the 
importance of testing, and the availability of TB diagnostics and treatment at local 
clinics.  Unfortunately the population-level impact of ECF on community TB prevalence 
remains unclear [45].   
ACF methods, on the other hand, are initiated by the health system and involve 
actively searching for additional cases in a particular time period, location, or group.  
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While ACF can take many forms (household contact tracing, case-driven contact referral, 
systematic screening of high risk populations, etc.), these methods have been shown to 
effectively identify more cases of TB, and to find them earlier in the disease course, than 
passive case detection methods alone [46,47].  However, like ECF strategies, the effects 
of ACF on community-level burden of TB have not been clearly demonstrated, and more 
research is needed.  While ACF strategies are frequently employed in many high-
resource, low TB burden settings, they have traditionally been considered too resource 
intensive to implement in high burden settings, which are often resource constrained.  
Recently, however, the WHO began scaling up its “3 Is Policy” for TB/HIV, which includes 
ACF and recommends TB screening for all HIV-infected individuals (so-called 
“intensified” [active] case-finding), as well as provision of isoniazid preventive therapy 
(IPT) for HIV-infected individuals in whom active TB is not suspected and the 
introduction of additional infection control measures in settings with a high risk of TB 
exposure [48].  South Africa has also been at the forefront of promoting ACF strategies 
for TB, virtually the only high burden country to do so at a population level.  
Unfortunately, research into the efficiency and yield of the various forms of ACF is 
lacking, especially in rural areas where these interventions may be more logistically 
difficult to implement.   
Despite these concerns, early evidence suggests that household contact tracing 
may be one potentially cost-effective ACF strategy that could feasibly be implemented 
in a rural, high-burden setting [49].  Previous research has found higher rates of TB 
among the household contacts of adults with recently-diagnosed active TB disease as 
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compared to the general population [50,51], suggesting that the household is an 
important setting for TB transmission.  However, the role of TB transmission within the 
household—and thus the yield and efficiency of household contact tracing—may differ 
according to the underlying TB incidence rate in the wider community.   
Increasing TB case-notification rates in rural, high-burden areas presents unique 
logistical and implementation challenges that need to be better understood.  ACF 
interventions such as household contact tracing may provide efficient, cost-effective 
approaches to bolster TB diagnosis and treatment rates in these settings, but need to be 
rigorously evaluated under operational conditions.  The objective of Aim 1 of this 
analysis is to estimate the yield (defined as the number of new cases of TB identified 
among household contacts per index case traced) of a household contact tracing 
intervention implemented in a rural South African setting, and compare our findings to a 
similarly structured intervention conducted in a high-burden, peri-urban area in South 
Africa.  To accomplish this, adults newly diagnosed with active, pulmonary TB (“index 
cases”) were recruited from public clinics, after which study staff visited the household 
and collected sputum from all household contacts to be tested for TB via sputum smear 
microscopy and culture.  Individuals under the age of five and/or positive for TB were 
referred to routine health services for further evaluation/treatment.  Our findings will 
inform government officials and policy makers in this and other similar settings 
regarding potential implementation and scale-up of household contact tracing 




Diagnostic Tests for TB 
Appropriate diagnostic tests for TB are another vital part of TB case-finding and 
prevention in high-burden settings.  Quality assured diagnostic tests are a crucial to the 
appropriate care of TB patients, and their improper deployment can lead to missed TB 
cases (resulting in preventable morbidity, mortality, and further disease transmission), 
unnecessary TB treatment for false-positive cases, as well as an over-burdening of the 
health system and wasted healthcare resources.  The number of TB diagnostics available 
to healthcare providers has also increased markedly in recent years.  However, their 
effectiveness use depends on the development of new TB screening and diagnostic 
algorithms, training for laboratory staff and healthcare providers on the tests’ proper 
use,  improvement of laboratory infrastructure, and country-level policy reform.  These 
activities should be informed by research on the impact and cost-effectiveness of 
various diagnostic tests and testing algorithms in specific settings.   
 The use—and potential misuse—of interferon-gamma release assays (IGRAs) 
provides one such opportunity for research.  IGRAs, including QuantiFERON-TB Gold in 
Tube (Cellestis, Carnegie, Australia) and T-SPOT.TB (Oxford Immunotec, Oxfordshire, UK) 
are immunological tests designed to detect latent tuberculosis infection (LTBI) in high-
income, low TB-burden settings.  IGRAs offer a number advantages over tuberculin skin 
testing (TST, the traditional test for LTBI), including a higher specificity and a lower risk 
of Bacille Calmette-Guerin (BCG) vaccine cross-reaction [54].  Unlike TST, IGRA testing 
utilizes a blood sample for testing, and does not require patients to return to the clinic 
24-48 hours later to have the test read, making it easier to implement.  Like TST, 
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however, IGRAs cannot differentiate between latent TB infection and active TB disease 
[55]. 
 Because of this inability to distinguish between latent and active TB, the WHO 
does not recommend the use of IGRAs as a test for the detection of active pulmonary 
TB, nor does the WHO recommend IGRAs a TST replacement in low- and middle-income 
countries [56].   Despite recommendations against the use of IGRAs in these settings, 
concern is mounting in countries such as India and China that IGRAs are being used off-
label as a test for active TB [57–60].  The use of IGRAs for the diagnosis of active disease 
in a setting like India, with background rates of LTBI as high as 40% or more [61], would 
result in large numbers of false positive TB diagnoses [18,62,63] (a test that is positive 
among all people with LTBI is likely to have a specificity of 60% or less when used for 
active TB in this context).  Over-diagnosis of TB due to the utilization of tests with a poor 
specificity for active TB represents a potential waste of scarce healthcare resources, and 
may expose patients to avoidable risks resulting from unnecessary treatment.   
 The population level outcomes of various TB diagnostic tests can be quantified 
through the use of decision analysis, an algorithmic approach that allows researchers to 
estimate the incremental costs and consequences of various courses of action (here, TB 
diagnostic algorithms) [64].  Decision analysis also enables researchers to incorporate 
uncertainty into their estimates through probabilistic sensitivity analyses, and to identify 
factors that have the greatest influence on the outcome of interest [64].  This approach 
is especially useful for comparing multiple alternatives, and provides an estimate for the 
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incremental cost-effectiveness of various options compared to an appropriate baseline 
scenario. 
 For Aim 2 we used decision analysis to estimate the incremental costs (from the 
Indian healthcare sector perspective) and consequences (including deaths, DALYs, false-
positive diagnoses, and secondary TB cases averted) of 4 different diagnostic algorithms: 
A reference scenario of clinical examination and non-microbiological tests, clinical 
diagnosis plus sputum smear microscopy, clinical diagnosis plus IGRA, and clinical 
diagnosis plus Xpert MTB/RIF (with and without the additional cost of multidrug-
resistant TB (MDR-TB) treatment).  This analysis was based on a hypothetical cohort of 1 
million adult Indian TB suspects, similar in HIV prevalence/access to ARVs to that 
observed amongst adults tested for TB each year in India.   
We hypothesized that, in a setting with high background rates of LTBI, IGRAs 
would be less cost-effective than other diagnostic tests with a higher specificity for 
active TB, due in large part to the cost of treating the substantial number of false-
positive cases generated.  These results will provide quantitative data to support 
training and advocacy efforts around the proper use (or non-use) of IGRAs in India, and 
other low-/middle-income country settings where LTBI prevalence is high.   
 
Isoniazid Preventive Therapy 
After high-risk individuals are screened for active TB, appropriate therapy (either 
curative, for those with active TB disease, or preventative, for those without active 
disease) is vital in preventing TB related morbidity and mortality, as well as further 
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secondary disease transmission.  This is particularly true for people living with HIV 
(PLHIV), who are at high risk for TB reactivation and TB-related death [65].  While 
antiretroviral therapy can reduce the risk of TB disease in PLHIV (through reconstitution 
of the immune system), the risk of TB reactivation remains higher among PLHIV on ARVs 
compared to HIV-uninfected individuals [66,67].  This differential risk is greatest during 
the first six months of ARVs [68].  Isoniazid preventive therapy (IPT) has been shown to 
reduce the risk of TB disease in PLHIV (in whom active TB disease has   been excluded) 
[69] above and beyond the effects of ARVs alone [68,70,71], and can be safely 
administered concurrently with ARVs [72].  When administered this way, IPT and ARVs 
have demonstrated a synergistic effect in reducing the risk of TB reactivation among 
PLHIV.   
 The WHO recommends 6 months of IPT be offered to all PLHIV in whom active 
TB disease is not suspected [73], though globally IPT coverage remains stubbornly low 
[74].  The first HIV diagnosis may represent an effective opportunity to initiate IPT, since 
these appointments occur in-person and typically involve counseling and referrals to 
routine healthcare services.  An on-going cluster-randomized trial of TB diagnostics for 
the exclusion of active TB among newly diagnosed PLHIV in rural Malawi has 
demonstrated high rates of acceptability of IPT when prescribed in this manner; of the 
1,011 individuals eligible for IPT, more than 99% initiated therapy during the first two 
phases of the study (Unpublished data).  Importantly, strategies for IPT eligibility 
screening and provision at the time of the first HIV diagnosis offer the opportunity to 
identify individuals at highest risk of TB disease (and who therefore stand to benefit the 
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most from IPT) in a routine clinical setting.  Such an approach has the potential to better 
integrate TB/HIV care in high dual-burden settings in an efficient, cost-effective manner. 
 While IPT initiation rates may increase if isoniazid is prescribed to PLHIV when 
HIV is first diagnosed, monitoring for side-effects and ensuring IPT completion remains a 
source of concern.  Even among successful initiators, IPT completion may be hindered 
by fears of stigma, limited funds for transportation, and a desire to avoid taking 
medications when symptoms are absent [75].  Identifying risk factors for non-
completion may help inform targeted interventions that could boost completion rates 
and reduce TB risk among PLHIV, especially during the crucial months before and 
immediately after ARV initiation.  Characterizing individuals most at risk of IPT non-
completion, or particular groups that may most benefit from targeted support during 
preventive treatment, may help improve rates of IPT completion, thereby reducing 
incident TB disease among newly diagnosed PLHIV.  
In an effort to inform such interventions, for Aim 3 we explored factors 
associated with IPT completion among a cohort of recently diagnosed HIV patients in 
rural Malawi, a high TB/HIV burden country.  This analysis is nested within a larger 
cluster randomized trial of TB diagnostics in newly diagnosed PLHIV.  Participating 
individuals were screened for symptoms of active TB at the time of their first HIV 
diagnosis.  Asymptomatic individuals were offered IPT if they were eligible, while 
symptomatic individuals underwent additional microbiological testing for TB.  Those 
testing negative were considered eligible for IPT if/when their TB symptoms resolved.  
Individuals initiating IPT were followed-up during routine clinical visits over the year 
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following their HIV diagnosis.  We explored clinical and demographic factors associated 
with IPT completion among all individuals starting IPT during the first two phases of the 
study.  We hypothesized that individuals initiating ARVs would be more likely to 
complete IPT, which was dispensed during routine clinical visits, since these individuals 
were attending regular clinic appointments to receive their antiretroviral drugs.  
Possible risk factors (all of which are easily assessed during routine clinical contact) 
identified by this analysis could be used to design and target interventions to support 
individuals most at risk treatment default.    
These analyses focus primarily on interventions deployable in low-resource, rural 
settings, where TB prevention, diagnosis, and treatment are hampered by limited 
infrastructure, human and financial resource constraints, low population densities, long 
distances to health facilities, and high rates of poverty.  Most research on TB control, 
conversely, has been conducted in urban, and peri-urban settings where infrastructure 
and epidemic conditions may differ substantially.  Ensuring the feasibility and 
effectiveness of TB control interventions in rural, high-burden settings requires 
operational and implementation science research at every step of the TB case-finding 






Figure 1.1: TB Case-Finding and Prevention Pathway - Conceptual Framework 
 
 
Interventions can be targeted to points along the pathway, including 1) case detection strategies for improved TB case-finding, 2) the use of 
appropriate diagnostic tests for the cost-effective identification of active TB disease, 3) notification of patients, clinics, and surveillance systems of 
new TB cases, 4) the use of appropriate treatments for active TB disease or prevention of active disease among those eligible for preventive 
therapy.  Interventions to reduce treatment default and increase treatment completion help ensure that therapy is continued until cure to prevent 
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INTRODUCTION TO CHAPTER 2: 
The TB case-finding and prevention pathway begins with the identification of 
high risk populations in need of TB testing.  Previous research has demonstrated an 
increased risk of TB disease among the household contacts of active TB patients, 
especially those that are smear positive.  Household contact tracing, a form of active 
contact tracing, has been shown to be feasible and effective in high-income, low TB-
burden settings, but has long been considered impractical and infeasible to implement 
in high-burden, low-income settings.   However, given the challenge of TB control in this 
context and the potential for high yields of previously undiagnosed TB disease in TB-
patient households, these interventions deserve serious consideration as a tool to 
increase TB case notification rates.   
However, because their efficiency and effectiveness depends in part on setting-
specific factors such as the underlying transportation infrastructure, community socio-
economic status, distance to the health facilities, TB/HIV stigma (among others), the 
yield and cost-effectiveness of household contact tracing interventions may vary widely.  
This may be especially true when comparing urban and rural contexts.  Operational 
research on these setting-specific effects, including their influences on yield and cost, 
will be important in deciding how and where to implement ACF interventions.  This 
study explores the yield of an ACF intervention implemented in rural South Africa, and 








Background: Efficient and effective strategies for identifying cases of active tuberculosis 
(TB) in rural sub-Saharan Africa are lacking.   
Methods: Adults newly diagnosed with active TB were recruited from public clinics in 
Vhembe District, South Africa.  Study staff visited index case households and collected 
sputum specimens for TB testing via smear microscopy and culture.  We calculated the 
yield and the number needed to screen (NNS) to find one additional case.  Predictors of 
new TB among household contacts were evaluated using multilevel logistic regression, 
accounting for clustering by household. 
Results: We recruited 130 index cases and 282 household contacts.  After excluding 3 
prevalent cases, we identified 11 previously undiagnosed cases of culture- or smear-
confirmed TB, giving a prevalence of 3.9% (95% CI: 2.0-6.9%) among contacts, a yield of 
8.5 per 100 (95% CI: 4.2-15.1) index cases traced, and NNS of 12 (95% CI: 7-24).  The 
presence of TB symptoms was not associated with an increased odds of active TB (aOR: 
0.3, 95% CI: 0.1-1.4).    
Conclusions: Household contacts of recently diagnosed TB patients in rural South Africa 
have high prevalence of TB and can be feasibly detected through contact tracing, but 







More aggressive approaches to finding cases are essential if we are to accelerate 
the current slow decline in TB incidence [1].  While most TB control interventions have 
focused largely on urban, high-burden settings, high TB incidence rates have been 
observed in rural populations [2,3], where long distances [4], inadequate infrastructure, 
poor-quality health facilities, and limited human resources present major obstacles to 
active case finding efforts [5,6].  To date, the majority of research on active TB case 
finding has been done in urban, peri-urban, or congregate settings [7]; limited research 
has been done on the efficacy and feasibility of these interventions in rural areas. [8]  
Though unproven, it is also reasonable to believe that a higher proportion of TB 
transmission could occur in the household in rural settings, where fewer people may 
frequent high-transmission settings such as public transit, shebeens, or major public 
gatherings [9–11]. We therefore sought to determine the yield of a household-based 
active case-finding intervention in a rural region of South Africa, a country with high 
rates of both TB and HIV [12].  We aimed to estimate the prevalence of previously 
undiagnosed TB among household contacts of recently diagnosed adult TB patients, to 
calculate the number of index cases needed to screen (NNS) to identify one additional 
case of previously undiagnosed TB, and to qualitatively compare the yield, prevalence, 









This study took place in Vhembe District, a municipality in Limpopo Province, 
South Africa, that borders Zimbabwe and Botswana.  The district has a population of 
approximately 1.3 million, and a population density of 130 individuals per square mile 
[14].  At 350 per 100,000/year, Vhembe had the second lowest district-level TB 
incidence in South Africa in 2012 [15].   
 
Participants 
Adults recently diagnosed with TB at public clinics in the district (“index cases”) 
were consecutively asked to participate in the study.  Index cases were eligible to 
participate if they were 18 years of age or older, had a recorded TB diagnosis based on 
clinical evaluation and/or radiology (with or without bacteriological confirmation), had 
initiated TB treatment within the previous 30 days, had been a resident of Vhembe 
District for at least 6 months, had at least one household contact, and consented to a 
home visit by the study team (Figure 2.1).  A household contact was defined as any 
person living on the same residential plot who shared either the same residential 
structure or frequent meals with the index case.  Participating index cases provided 
written informed consent and completed a short survey that included demographics, TB 
and HIV clinical history, and directions to their home.  TB diagnosis and treatment data 






Trained study staff visited index case households within 2 weeks of recruitment.  
Household contacts were eligible to participate in the study if they met the definition of 
a household contact (described above) and provided informed consent.  Trained study 
staff administered similar brief surveys to all participating household contacts and 
collected sputum specimens for smear and culture in accordance with national 
guidelines [16].  TB testing, including fluorescence microscopy with auramine staining 
and culture (BAC-TEC MGIT 960, BD Diagnostics, Franklin Lakes, USA) was performed by 
South Africa’s National Health Laboratory System.  All household contacts under the age 
of 5 were referred for further clinical evaluation through routine services, according to 
South African guidelines [16].  Results from the laboratory tests were made available to 
study personnel, and all positive results were reported to clinical staff for initiation of TB 
treatment through routine clinical services.  Clinic records were evaluated to determine 
if individuals referred for treatment actually initiated anti-TB therapy.  We did not 
provide HIV testing, but referred individuals who did not know their HIV status, or who 
had not been recently tested, to the routine health services for voluntary HIV counseling 
and testing.   
If household contacts were not available for recruitment during the first study 
visit, study staff attempted to make an appointment to return to the home at a later 
time.  Study staff returned to each household up to three times to complete recruitment 




participants consented to receiving their results via phone, the study team called 
individuals who had negative smear and culture results.  
 
Statistical Analysis: 
Our primary outcome was the proportion of household contacts with newly 
diagnosed TB, confirmed by smear and/or culture positive for TB.  We calculated the 
yield of active case finding as the number of newly diagnosed TB cases among 
household contacts identified for every 100 index cases traced and also calculated the 
number of index cases needed to screen to identify one additional confirmed TB case.  
We constructed 95% confidence intervals (95% CI) around these estimates by assuming 
a binomial distribution (for prevalence) or a Poisson distribution (for yield). We 
examined univariate associations between our outcomes and potential predictors using 
Fisher’s exact tests and Wilcoxon/Mann-Whitney tests.  We used multilevel logistic 
regression modeling to examine the relationship between newly diagnosed TB and 
variables including demographics, laboratory results, symptom history, and index case 
characteristics, incorporating a random effects term to account for clustering at the 












Between December 1, 2013 and September 30, 2014, we recruited 130 of 156 
(83%) of eligible index cases from 27 participating public clinics in Vhembe District 
(Figure 2.1A).  Index cases were 56% male (73/130) and averaged 40 years of age 
(Interquartile range [IQR]: 31 – 49) (Table 2.1).  Nearly all participants spoke Tshivenda 
(126/130, 97%) and were born in Limpopo Province (127/130, 98%).   Just over 50% of 
index cases had completed at least some high school (73/130, 56%), and a similar 
proportion reported living in a female-headed household (67/130, 52%).  On average, 
household size was five people (IQR: 3-6), and the head of the household earned 
approximately 2,200 Rands (about US$200 in 2014) per month (IQR: 13-2350) from all 
formal and informal sources.  Index cases had lived in their current homes for 30 years 
on average (IQR: 20-40); only two reported living in their current home for one year or 
less. 
Of the 95% of index cases with known HIV status, 58 (47%) were living with HIV, 
less than 20% of whom (n=11) reported receiving antiretroviral therapy at the time of 
their TB diagnosis, though 71% (n=40) received their HIV and TB test results a month or 
less apart (40/56, 71%).  Only two index cases had documented drug-resistant TB.  A 
great majority of index cases reported having TB symptoms (cough, fever, night sweats, 
weight loss, and/or fatigue) at diagnosis (112/130, 86%), and a median duration of 






From 130 index case households visited, we recruited 282 household contacts 
(Figure 2.1B).  Household contacts were somewhat younger than index cases (median 
age: 26 years, IQR: 17-50, with 23% younger than 15 years old) and were more likely to 
be female (203/282, 72%) (Table 2.2).  Among adult participants (>18 years old) half had 
completed at least some high school (99/198, 50%).  Of the 119 household contacts 
willing to disclose their HIV status, 22 (19%) reported that they were living with HIV, 20 
(91%) of whom were receiving antiretroviral therapy.  Three participants reported that 
they were currently receiving treatment for TB and were excluded from subsequent 
analyses. Only 4% of household contacts (12/279) were unable to produce sputum of a 
sufficient quantity for testing; these individuals were analyzed as TB-negative.   
 
Yield and Number Needed to Screen: 
The intervention identified 11 new cases of confirmed active TB, for a household 
contact prevalence of 3,940 per 100,000 (95% CI: 1,980-6,940).  Of these, only one (9%) 
was smear-positive; the rest were positive on culture alone. An additional 18 individuals 
(6,450 per 100,000, 95% CI: 3,870-10,000) had cultures that were positive for non-TB 
mycobacteria. The intervention therefore yielded 8.5 previously undiagnosed TB cases 
(95% CI 4.2-15.1) for every 100 index cases traced, giving a number of index cases 
needed to screen, using culture, of 12 (95% CI: 7-24) to identify one new case of 





Predictors of TB 
Overall, 44% (n=122) of participating household contacts reported at least one 
TB symptom; these included cough (15%), fever (15%), lethargy (14%), loss of appetite 
(5%), weight loss (14%), and night sweats (18%), with a median duration of 75 days (IQR: 
14-365) and mean of 272 days.  Counterintuitively, contacts newly diagnosed with 
culture-confirmed TB had a markedly lower prevalence of symptoms, though this 
difference was not statistically significant (18% vs. 45%, p=0.120).  Only 29 contacts 
(24%) reporting seeking care for their symptoms; none of these individuals had 
confirmed prevalent TB. 
Compared to contacts without TB, those with newly diagnosed TB were more 
likely to live in female-headed households (82% vs. 51%, p=0.063) and to have 
completed more years of schooling (10 vs 8, p=0.023) on univariate analysis. We 
detected no differences in terms of BMI, smoking status, history of previous TB, and 
history of isoniazid preventive therapy (IPT).  All of the household contacts diagnosed 
with TB had started TB treatment by the end of the study period.  In a multilevel logistic 
regression model including both education and female-headed household status, both 
variables remained independent predictors of newly diagnosed TB (adjusted OR [aOR]: 
5.2, 95% CI: 1.1-25.4, for female-headed household, aOR: 8.2, 95% CI: 1.5-46.2, for 









This study found a high prevalence (nearly 4,000 per 100,000) of previously 
undiagnosed TB among household contacts of newly diagnosed TB patients, only one-
third lower than that (6,075 per 100,000) observed in a similar contact tracing study in 
an area with nearly three times the background incidence of TB [13].  The sensitivity of 
smear for culture-confirmed active TB in this population was less than 10%. This analysis 
demonstrates that, even in rural settings, household contact tracing can feasibly identify 
cases of active TB, but symptom screening is unhelpful in identifying TB cases.  
Additionally, we found that sensitive diagnostic tests may be required in order to 
effectively diagnose TB cases, which may substantially add to the expense of conducting 
active contact tracing in this setting.   
While the WHO recommends TB screening for the household contacts of newly 
diagnosed TB patients (because of their elevated risk of TB disease), they do not 
recommend a specific algorithm [17].  Instead WHO provides a range of potential 
algorithms, such as testing only those individuals with any cough, a cough of more than 
two weeks, or the presence of any TB symptoms (e.g. cough, fever, weight loss, night 
sweats, and/or lethargy) [17].  Had we used the presence of any cough to screen for 
household contacts at greatest risk for TB—and tested only these “highest risk” 
individuals—we would have missed all of the new TB cases, while screening for the 






The fact that the majority of new TB cases identified by this study were 
asymptomatic and smear negative indicates that household contact tracing in rural 
areas may identify cases of TB early, before substantial secondary transmission or TB-
related morbidity or mortality can occur.  Virtually all index cases recruited for our study 
were symptomatic, whereas household contacts with TB were actually less likely to 
report symptoms than their family members without active TB.  These findings suggest 
that TB cases captured by active contact tracing interventions are different than the 
cases captured by the routine system through passive case detection, and that the 
diagnostic tests and/or screening algorithms required to detect them differ as well.  Had 
household contacts been tested for TB using sputum smear microscopy alone, we would 
have missed more than 90% of all TB cases in our sample.   
Index cases in our study reported mean symptom durations of nearly 250 days 
before TB diagnosis, while smear/culture positive TB cases averaged only 11 days 
between symptom onset and the study visit.  This discrepancy indicates that substantial 
TB transmission may be occurring before individuals ever present to care in a passive 
case-detection setting.  This transmission can likely only be averted through active 
screening strategies such as contact tracing.   
We also identified a very high prevalence of non-TB mycobacteria (NTM) among 
household contacts, nearly three times as high as the prevalence of culture-confirmed 
TB 11% (95% CI: 7-15%).  Other studies from South Africa have also identified high rates 
of NTM infection [18,19].  This result raises questions regarding the timing of TB 




tracing.  On average speciation takes approximately 5 additional days [20] from the time 
a culture positive result is returned.  Avoiding treatment delays for those with active TB 
is paramount, but preventing unnecessary treatment should be an important 
consideration given the poor specificity of culture for TB (92%) in this population.   
This study has a number of important limitations. First, although we screened 
more than 280 household contacts, our sample size of TB cases was small, leaving us 
without power to detect modest differences between those with and without TB.  
Because we recruited index cases with and without laboratory-confirmed TB, it is 
possible that some of the participating index cases did not have active TB disease.  
However, this study sought to explore the feasibility and effectiveness of household 
contact tracing under operational conditions in which TB is not always bacteriologically 
confirmed.  Finally, we were unable to perform HIV testing or TB testing with Xpert 
MTB/RIF for household contacts.  Further studies of TB contact tracing in rural settings 
could seek to expand the sample size, evaluate novel diagnostic tools (e.g., Xpert 
MTB/RIF), study the cost-effectiveness of active contact tracing in this setting, and 
elucidate the relationships between HIV and TB status among household contacts. 
 
Conclusion: 
Household contact tracing of newly diagnosed TB patients in a rural South 
African setting feasibly found high prevalence of previously undiagnosed TB, nearly all of 
which was smear-negative.  Symptom screening was not an effective strategy for 




diagnostic tests than smear, should be seriously considered in high-burden settings, 








Figure 2.1A & 2.1B: Study Flow Diagram 
 
 
* Hospitalized patients were unable to be recruited for this study  
** Participants were ineligible due to age <18 years (N=1), a time between TB treatment initiation and 
study screening of >30 days (N=5), having no household contacts (N=22), or primary residence outside of 
the study district (N=9).   















New TB in HH 
(N=9) 
No New TB in 
HH (N=121) P-value* 
N (%) N (%) N (%) 
Female Sex 57 (44%) 3 (33%) 54 (45%) 0.731 
Age (Median, IQR) 40 (31-49) 36 (31-48) 39 (31-49) 0.831 
Female-Headed Household 67 (52%) 7 (78%) 60 (50%) 0.166 
Head of HH Income (Median, 
IQR) 
1270 (13-2350) 2500 (1270-6300) 1270 (0-2000) 0.047 
Education     
8th grade or less 40 (31%) 4 (44%) 36 (30%) 
0.278 At least some high school 73 (56%) 3 (33%) 70 (58%) 
More than high school 17 (13%) 2 (22%) 15 (12%) 
Unemployed 73 (56%) 6 (67%) 67 (55%) 0.731 
Number of HH members, by 
Self-Report (Median, IQR) 
5 (3-6) 6 (5-6) 4 (3-6) 0.130 
Number of HH Contacts 
Participating in Study 
(Median, IQR) 
2 (1-3) 3 (2-6) 2 (1-3) 0.005 
Years lived in HH (Median, 
IQR) 
30 (20-40) 37 (28-43) 30 (19-39) 0.235 
Previous TB 15 (12%) 1 (11%) 14 (12%) 1.0 
TB Symptoms     
Cough 58 (45%) 4 (44%) 54 (45%) 1.0 
Fever 45 (35%) 1 (11%) 44 (36%) 0.162 
Fatigue 64 (49%) 4 (44%) 60 (50%) 1.0 
Loss of appetite 25 (19%) 1 (11%) 24 (20%) 1.0 
Weight loss 84 (65%) 5 (56%) 79 (65%) 0.720 
Night sweats 55 (42%) 5 (56%) 50 (41%) 0.493 
At least one TB symptom 112 (86%) 7 (78%) 105 (87%) 0.611 
Symptom duration     
No symptoms 18 (14%) 2 (22%) 16 (13%) 
0.357 
<1 month 57 (44%) 3 (33%) 54 (45%) 
1-6 months 32 (25%) 1 (11%) 31 (26%) 
>6 months 23 (18%) 3 (33%) 20 (17%) 
Smear Positive** 44 (73%) 2 (29%) 42 (79%) 0.012 
Xpert Positive† 55 (86%) 2 (67%) 53 (87%) 0.370 
* Categorical variables were tested using Fisher’s Exact Test, and continuous variables were tested with a Ranksum test 
** 70 individuals were missing smear results in the clinic TB register and/or index case TB card (68 index cases living in households 
with no new TB cases, and 2 individuals living in households with ≥1 new TB case) 
† 66 individuals were missing Xpert results in the clinic TB register and/or index case TB card (60 index cases living in household with 









Table 2.2: Household Contact Demographic and Clinical Information 










N (%) N (%) N (%) 
Female Sex 201 (72%) 10 (91%) 191 (71%) 0.301 
Age Category     
Under 14 60 (22%) 2 (18%) 58 (22%) 
0.943 
15-39 117 (42%) 6 (55%) 111 (41%) 
40-64 66 (24%) 2 (18%) 64 (24%) 
65 and Older 36 (13%) 1 (9%) 35 (13%) 
Female-Headed 
Household 
146 (52%) 9 (82%) 137 (51%) 0.063 
Head of HH Income 
(Median, IQR) 
1270 (0-2500) 1270 (1270-6300) 1270 (0-2350) 0.101 
Education     
8th grade or less 140 (50%) 3 (27%) 137 (51%) 
0.079 
At least some high 
school 
114 (41%) 5 (45%) 109 (41%) 
More than high school 25 (9%) 3 (27%) 22 (8%) 
Unemployed 149 (53%) 8 (73%) 141 (53%) 0.229 
Number of HH 
members (Median, 
IQR) 
5 (4-7) 6 (5-8) 5 (4-7) 0.248 
HIV Status     
HIV-Infected 19 (7%) 0 (0%) 19 (7%) 
0.792 HIV-Uninfected 97 (35%) 3 (27%) 94 (35%) 
HIV Status Unknown 163 (58%) 8 (73%) 155 (58%) 
TB Symptoms     
Cough 41 (15%) 0 (0%) 41 (15%) 0.377 
Fever 42 (15%) 1 (9%) 41 (15%) 1.0 
Fatigue 40 (14%) 0 (0%) 40 (15%) 0.374 
Loss of appetite 13 (5%) 1 (9%) 12 (4%) 0.414 
Weight loss 38 (14%) 1 (9%) 37 (14%) 1.0 
Night sweats 51 (18%) 1 (9%) 50 (19%) 0.695 
At least one TB 
symptom 
122 (44%) 2 (18%) 120 (45%) 0.120 
Symptom duration     
No symptoms 157 (56%) 9 (82%) 148 (55%) 
0.465 
<1 month 53 (19%) 1 (9%) 52 (19%) 
1-6 months 32 (11%) 1 (9%) 31 (12%) 
>6 months 37 (13%) 0 (0%) 37 (14%) 
Smear Positive 1 (0.4%) 1 (9%) -- -- 
Culture Positive 28 (11%) 10 (91%) 18 (8%) -- 
MTB Culture Positive 10 (4%) 10 (91%) -- -- 
Smear and/or MTB 
Culture Positive 




Table 2.3: Factors Associated with Newly Diagnosed TB among Household Contacts 
Variable 
Unadjusted Adjusted* 
OR (95% CI) aOR (95% CI) 
Female Sex 4.06 (0.49-33.71) 4.51 (0.54-37.65) 
Age (per 10 year increase) 0.97 (0.72-1.30) 1.00 (0.71-1.41) 
Female-headed household 4.48 (0.87-23.08) 5.19 (1.06-25.44) 
Head of household income (Per 500 
Rands) 
1.06 (0.96-1.17) 1.03 (0.94-1.14)  
Education**   
8th grade or less Ref Ref 
At least some high school 2.14 (0.49-9.40) 2.08 (0.47-9.19) 
More than high school 6.05 (1.07-34.40) 6.88 (1.19-39.66) 
Unemployed 2.28 (0.56-9.25) 2.48 (0.62-9.96) 
Number of HH members (Index case 
self-report) 
1.12 (0.88-1.43) 1.14 (0.92-1.43)  
TB Symptoms   
At least one TB symptom 0.26 (0.05-1.30) 0.29 (0.06-1.44) 
Symptom duration   
No symptoms Ref Ref 
<1 month 0.32 (0.04-2.80) 0.35 (0.04-2.98) 
>=1 month 0.22 (0.02-1.90 0.25 (0.03-2.13) 
* Adjusted for Education status 
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COSTS AND CONSEQUENCES OF USING INTERFERON-γ RELEASE ASSAYS FOR 


























INTRODUCTION TO CHAPTER 3 
 The diagnosis or exclusion of TB disease in high risk individuals in paramount, 
whether these individuals are identified through passive case finding efforts (such as 
self-presentation), or active approaches such as symptom screening and the household 
contact tracing intervention described in Chapter 2.  The process of diagnosing a TB case 
has benefited immensely from the development of new TB diagnostics in recent years.  
While new tests are often more sensitivity and specific than earlier tests, their effective 
deployment requires additional healthcare provider and laboratory training, as well as 
the development and dissemination of new diagnostic algorithms and testing guidelines.  
When any of these are lacking, true TB cases may be missed (leading to increased 
morbidity and mortality, and further disease transmission), true negatives may be 
falsely diagnosed and treated, and limited healthcare resources may be wasted.  
Decisions on the most efficient use of new TB diagnostics may be informed by 
quantitative analyses, such as the one in Chapter 3.  This cost effectiveness analysis 
explores the costs and consequences of the use of interferon-gamma release assays 
(IGRAs), which are increasingly being used off-label in the Indian private sector to 
diagnose active TB disease.  In this chapter we explore the health system costs and 
patient consequences associated with the use of IGRAs in India in order to better inform 
healthcare providers, laboratory professionals, and policymakers on the effects of using 








There is growing concern that interferon-γ release assays (IGRAs) are being used off-
label for the diagnosis of active tuberculosis (TB) disease in many high-burden settings, 
including India, where the background prevalence of latent TB infection is high.  We 
analyzed the costs and consequences of using IGRAs for the diagnosis of active TB in 
India from the perspective of the Indian TB control sector.   
Methods and Findings: 
We constructed a decision analytic model to estimate the incremental cost and 
effectiveness of IGRAs for the diagnosis of active TB in India.  We compared a reference 
scenario of clinical examination and non-microbiological tests against scenarios in which 
clinical diagnosis was augmented by the addition of either sputum smear microscopy, 
IGRA, or Xpert MTB/RIF.  We examined costs (in 2013 US dollars) and consequences 
from the perspective of the Indian healthcare sector.  Relative to sputum smear 
microscopy, use of IGRA for active TB resulted in 23,700 (95% uncertainty range, UR: 
3,800 – 38,300) additional true-positive diagnoses, but at the expense of 315,700 (95% 
UR: 118,300 – 388,400) additional false-positive diagnoses and an incremental cost of 
US$49.3 million (95% UR: $34.9 – $58.0 million) (2.9 billion Indian Rupees). Relative to 
Xpert MTB/RIF (including the cost of treatment for drug resistant TB), use of IGRA led to 
400 additional TB cases treated (95% UR: [-8,000] – 16,200), 370,600 (95% UR: 252,200 




disability-adjusted life years averted, and US$14.6 million (95%UR: [-$7.2] – $28.7 
million) (854 million Indian Rupees) in additional costs.  
Conclusion: 
Using IGRAs for diagnosis of active TB in a setting like India results in tremendous 
overtreatment of people without TB, and substantial incremental cost with little gain in 
health. These results support the policies by WHO and Standards for TB Care in India, 

























Interferon-gamma Release Assays (IGRAs), including QuantiFERON-TB Gold In 
Tube (Cellestis, Carnegie, Australia) and T-SPOT.TB (Oxford Immunotec, Oxfordshire, 
UK), are immunological tests that are widely used to detect latent tuberculosis infection 
(LTBI) in high-income settings.  IGRAs have higher specificity than tuberculin skin testing 
(TST), are less likely than TSTs to cross-react with the Bacille Calmette-Guerin (BCG) 
vaccine, and correlate well with M. tuberculosis exposure [1], though stronger 
association with progression to active disease has not been conclusively shown [2]. 
  While IGRAs are recommended for the diagnosis of LTBI in many high-income 
countries, they are not recommended by the World Health Organization (WHO) as a TST 
replacement for LTBI diagnosis in low and middle income countries [3].  Furthermore, in 
no setting are IGRAs recommended for detection of active pulmonary TB [3], since 
IGRAs (like TST) cannot differentiate latent infection from active TB disease [4].  
In high-burden settings, where 40% or more of the general population is latently 
infected with TB [5] and therefore likely to test IGRA-positive [6–8] (i.e., a test that is 
positive among all people with latent TB is likely to have a specificity of 60% or less 
when used for active TB), use of IGRAs to diagnose active pulmonary TB is particularly 
problematic. This concern equally applies to the use of tuberculin skin test (TST) for 
active TB.  Nevertheless, in many high-burden countries, including India, there is 
growing concern that IGRAs (and, to a lesser extent, TST) are being used off-label, 
particularly in the private sector, for the diagnosis of active TB [9,10].  In India, 




India) as “TB Platinum,” names that provide poorly-trained healthcare providers little 
guidance as to their intended use.   In China, domestic IGRAs are made by several 
companies, and publications from China suggest their use to diagnose active TB in that 
setting as well [11,12]. 
Although the use of IGRAs and TST for active TB is discouraged by the Indian 
Revised National TB Control Programme (RNTCP) and the Standards for TB Care in India 
[13], IGRAs are not banned, and there is growing concern that the use of IGRAs has 
increased since the ban on antibody-based serological TB tests in 2012 [14,15].   Market 
research conducted in 2012-2013 by the Clinton Health Access Initiative found that 
approximately 12% of private laboratories in India offered QuantiFERON TB Gold tests 
[16].  As the economic and patient consequences of this practice remain unclear, we 
analyzed the costs and consequences of using IGRAs for the diagnosis of active 
pulmonary TB in India from the perspective of the Indian TB control sector.   
 
MATERIALS AND METHODS: 
 
Study Design and Population: 
To estimate the costs and consequences of IGRAs for the diagnosis of active 
pulmonary TB in adults, we adapted our prior decision analysis model of serological TB 
tests in India [17]  (Figure 3.1).  The full model can be seen in the Supplemental Material 
(S1 File).  We took as our study population one million Indian adults in whom TB is 
clinically suspected, with a nationally representative prevalence of latent TB infection, 




hypothetical study cohort is representative of adults in India presenting for TB diagnosis 
in settings with access to serological testing, and is intended to approximate the annual 
costs and outcomes among all adult patients in India receiving serological testing for 
suspected active TB disease.  We examined costs (measured in 2013 US dollars) and 
effects from the perspective of the Indian healthcare sector (including both public and 
private sectors), with future discounting of 3% per year.  Outcomes included disability-
adjusted life years (DALYs) averted (without age weighting), TB cases treated, and false-
positive treatments (people without active TB who are inappropriately treated for active 
TB). 
We took our reference (base-case) scenario to consist of the existing standard of 
care for TB diagnosis, but without the use of any microbiological tests.  Thus, this 
scenario would consist of clinical evaluation plus any non-microbiological tests (e.g. 
chest X-ray) that might be routinely performed for TB diagnosis in a typical Indian 
setting.  We compared this  reference scenario against scenarios in which this standard 
of care was augmented by the addition of microbiological tests, namely sputum smear 
microscopy, IGRA, or Xpert MTB/RIF (a WHO-endorsed, sputum-based molecular test 
for TB)  [18].  In making this comparison, we assumed that any individual who would be 
treated for TB in the reference scenario would also be treated for TB after performance 
of a microbiological test, even if that test result was negative.  (For example, someone 
with a strong clinical suspicion of TB, but a negative smear, IGRA, or Xpert would still be 




would not be taken as an indication to discontinue treatment among individuals started 
on anti-TB therapy.   
In addition to smear, IGRA, and Xpert MTB/RIF, we also examined a scenario 
including mycobacterial culture.  We do not present those findings in detail, however, as 
research has shown that culture results have limited impact on physician’s treatment 
decisions in India [19].  We included the effects of multi-drug resistant TB (MDR-TB) on 
each these diagnostic scenarios, assuming an MDR-TB prevalence of 2.1% among all 
newly diagnosed Indian adult TB cases [20], and examined the costs and consequences 
of diagnosing and treating MDR-TB for the Xpert arm (as, unlike smear or IGRA, Xpert is 
capable of diagnosing resistance to rifampin, a proxy measure for MDR-TB).  Though 
recommended by the RNTCP in certain situations, drug-sensitivity testing (DST) is not 
widely available in India [21], and therefore costs associated with DST were not included 
in the non-Xpert MTB/RIF arms.  We took as our primary outcomes the incremental 
costs and consequences (including DALYs, secondary TB transmissions, false positive TB 
cases diagnosed, and TB cases treated) of diagnosis with either IGRA or Xpert MTB/RIF, 
compared to the reference scenario.  
 
Parameters and Assumptions 
Assumptions regarding the availability and turnaround time for sputum smear 
microscopy are as previously reported [17], and include a one week turnaround time for 
sputum smear microscopy with a loss to follow-up during this interval of 15% [22].  We 




with a 1-week turnaround time and a loss-to-follow-up rate similar to that of sputum 
smear microscopy.  To be conservative, Xpert MTB/RIF was assumed to have a delay 
between testing and treatment initiation of 7 days [23], and the same loss to follow-up 
as with IGRAs or sputum smear microscopy.  Diagnostic testing cost estimates were 
based on published data, inflated to the year 2013 using the Indian GDP deflator [24], 
followed by conversion into US dollars at the 2013 exchange rate [25], where applicable.   
We estimated the cost of sputum smear microscopy to be US$3 (range: US$1 – 
5, for two smears) for each TB suspect tested [26].  Based on an internal survey 
(unpublished) of private laboratories [27], we estimated that IGRAs would cost US$30 
(range: US$20 – 50) per test, while Xpert MTB/RIF was assumed to cost US$25 per test 
(range: US$20 – 57) [28,29].  After analysis overall costs were converted into 2013 
Indian Rupees (INR) from 2013 US dollars using historical exchange rates [25], and cost 
outcomes are presented in both currencies. 
Test accuracy estimates were obtained from the published literature, including 
meta-analyses where available.  IGRA accuracy values were based on the QuantiFERON-
TB Gold test, and obtained from studies performed in low- and middle-income country 
settings.   While the T-SPOT.TB IGRA is unavailable in India, QuantiFERON-TB Gold In-
Tube is available and commonly utilized, especially in the private sector [30] .   For our 
analysis we used an IGRA sensitivity of 0.84 [4] (range: 0.56 – 0.96).  For the purposes of 
illustrating the sensitivity of our model to a wider interval of possible sensitivities of IGRA tests, 
we used a wider range for sensitivity analysis around this variable than the published pooled 




suspected TB in low and middle income countries) of 0.52 (range: 0.40 – 0.79) [4].  
Additional parameter values are given in Table 3.1. 
 
Sensitivity Analysis 
We performed one-way sensitivity analyses on all model parameters, taking as 
the primary outcome the incremental costs and consequences of IGRA compared to the 
reference standard.  Ranges for each model parameter are listed in Table 3.1.  We 
performed additional two-way sensitivity analyses on those parameters with the 
greatest effects on model outcomes.  Where data were lacking in regards to an 
appropriate range for the sensitivity analysis for a given parameter, we varied each 
parameter value by +/- 25% beyond its base value.    
Finally, we performed a probabilistic sensitivity analysis (PSA) to incorporate 
uncertainty in all model parameters.   In this analysis, we simultaneously varied all 
model parameters using Monte Carlo simulation (10,000 simulations), assuming that all 
parameters followed beta distributions with a mode equal to the most likely value (in 
Table 3.1) and an alpha (shape) parameter of four, with two exceptions.  First, since it 
was unlikely that accuracy values (sensitivity and specificity) would approach zero, we 
varied these parameters using triangular distributions with minimum and maximum 
values based on the upper and lower estimates derived from systematic reviews where 
possible, and other published literature values where not.  Second, some values (e.g., 
costs) do not have a natural upper bound; for these parameters, we assumed a gamma 




full model used for the PSA can be seen in the Supplemental Material (S2 File).  All 
analyses were conducted using TreeAge Pro 2013 (TreeAge Software, Inc., 




Our hypothetical cohort of one million people with TB symptoms included 
143,000 individuals with active TB.  When used alone, we estimated that clinical 
examination and reference scenario tests (such as X-ray) would detect 75,700 (53%) 
(95% Uncertainty Range, UR: 36,000 – 124,900) of these patients (Figure 3.2).  Addition 
of sputum smear microscopy to this algorithm increased the overall yield to 108,400 
(76%) (95% UR: 53,800 – 174,300) (Figure 3.2).  Use of Xpert MTB/RIF instead of smear 
for all members of the cohort identified an additional 23,300 cases relative to smear 
(yield: 131,700, 92%) (95% UR: 64,100 – 206,100), while also identifying 55,000 fewer 
false-positive cases than smear microscopy (95% UR: 5,100 – 198,800).  Use of 
mycobacterial culture methods (under the additional assumption that culture results 
could largely be translated into treatment decisions, with 10% additional loss to follow-
up) resulted in qualitatively similar outcomes as those observed in the Xpert MTB/RIF 
arm (data not shown).   
Use of IGRA rather than smear had a similar yield of true-positive diagnoses as 
Xpert (132,100 cases, 93%) (95% UR: 62,800 – 203,000), but at the expense of 438,200 




every true-positive – and 315,700 (95% UR: 118,300 – 388,400) more false-positives 
than sputum smear microscopy.   
The cost of IGRA-based diagnosis, from the Indian healthcare perspective, was 
also high.  For every million individuals tested by IGRA rather than sputum smear 
microscopy, the incremental cost of TB diagnosis and treatment was US$49.4 million 
($67.3 million with IGRA vs. $18.0 million with sputum smear microscopy) (95% UR: 
$34.9 – 58.0 million) (Figure 3.2).  The US$49 million (2.9 billion Indian Rupees, INR) in 
incremental costs reflected approximately US$27 million (1.6 billion INR) in additional 
diagnostic test costs, US$2 million (117 million INR) in the treatment of additional true-
positive cases identified with IGRAs, and nearly US$21 million (1.2 billion INR) for the 
treatment of false-positive cases – people without active TB who nevertheless received 
six months of anti-TB drugs.  
Similarly, although the cost of diagnosis with IGRA and Xpert MTB/RIF was 
similar, the total healthcare cost of IGRA was nearly US$15 million greater (95% UR: $-
7.2 – 28.7 million) (854 million INR) than Xpert (US$67.3 million vs. $52.7 million) (3.9 
billion vs. 3.1 billion INR), due to the large numbers of false-positive diagnoses triggering 
inappropriate treatment (Figure 3.2).  Incorporating the possibility of MDR treatment 
for IGRA-diagnosed false positive cases would raise the total costs of the IGRA scenario 
even more.  As a result of the poor specificity of IGRA, we estimated that Xpert MTB/RIF 
would avert more DALYs, and at lower cost, than IGRAs (as used for diagnosis of active 
TB), even after including the costs of treating drug-resistant TB in the Xpert MTB/RIF 




true TB cases (95% UR: -8,000 – 16,200), and made 370,600 more false-positive 
diagnoses (95% UR: 252,200 – 441,700).  Relative to sputum smear microscopy alone, 
Xpert MTB/RIF cost US$345 (20,200 INR) per DALY averted, similar to prior analyses [28] 
, while the IGRA strategy was dominated by the Xpert strategy.   
In one-way threshold analyses based on the pre-specified ranges of all variables 
in the model (Figure 3.3), the scenario using Xpert MTB/RIF averted more DALYs than 
IGRAs at IGRA sensitivities of 95.7% or less, very near the upper bound of 96%.  When 
considering the cost of MDR treatment based on Xpert results, IGRA-based algorithms 
were more costly than Xpert-based ones unless the unit cost of Xpert exceeded US$39 
(2,280 INR).  Xpert MTB/RIF remained less costly than IGRA testing until the average 
cost of MDR treatment exceeded US$5100 (298,000 INR) per person, near the highest 
average cost of MDR treatment in India from 2008-2013 (US$5500) [31] (322,000 INR).  
In other scenarios tested, Xpert MTB/RIF (including MDR treatment) was both less 
expensive and more effective than IGRA testing.  
In two-way sensitivity analyses, even with a specificity of 62% (the upper bound 
of IGRA specificities tested), IGRAs only averted more DALYs than Xpert MTB/RIF in 
situations in which the IGRA sensitivity was over 94% (Figure 3.4).  In terms of overall 
costs, two-way sensitivity analysis found that even if IGRAs cost only US$20 (1,170 INR) 
per test (the lowest bound of IGRA costs tested), algorithms using Xpert MTB/RIF would 
still be less costly below a unit price of US$29 (1,700 INR) per Xpert test.   
In probabilistic sensitivity analysis, IGRA was more costly than Xpert (without 




treatment) in 89% of simulations.  Xpert averted more DALYs than IGRAs in 96% of 




More than 2 million individuals are diagnosed with active TB every year in India, 
leading to approximately 300,000 TB-attributed deaths [20] .  Although diagnosis and 
treatment of LTBI is a valid TB control strategy in specific high-risk groups [32], given 
current resource constraints, national TB programs, including the Indian RNTCP, 
prioritize treatment of active TB over LTBI.  A ban on antibody-based serodiagnostic 
tests and a provider preference for blood-based rather than sputum-based diagnostics 
[33]  has expanded the market for IGRAs.  Indeed, Indian physicians rarely treat LTBI in 
routine clinical practice [34], but tests for LTBI, including not only IGRAs but also TST, are 
commonly used [15].  Our analysis shows the likely adverse economic consequences to 
the healthcare system when IGRAs are utilized to diagnose active TB in areas with high 
background prevalence of LTBI.  Given the growing popularity of IGRAs in other 
countries such as China, where evidence suggests the tests are also being used to 
diagnose active TB disease, these economic and healthcare system concerns likely 
extend to settings beyond India as well [11,12]. 
Based on the prevalence of LTBI in India’s adult population [5] , IGRAs – even 
with perfect specificity for their designed indication (diagnosis of LTBI) – would be 
positive in more than 40% of all people without active TB, meaning that for every 




falsely diagnosed and subjected to six months of treatment.  Treating these individuals 
for active TB – even in a country with TB treatment costs among the lowest in the world 
– would cost US$36.1 million (2.1 billion INR) for every 1 million people with TB 
symptoms.  By comparison, appropriate treatment for all individuals in the cohort with 
MDR-TB – an expense that has, in the past, been argued to be unsupportable by the 
Indian TB control program – would cost US$7.6 million (440 million INR), and even the 
use of commercial serology – now banned due to its poor performance – would cost less 
(US$31.7 million, 1.9 billion INR) and make fewer false-positive diagnoses (75,500 vs. 
438,200) than IGRAs [17]. While we did not explicitly model the use of TST for active TB 
diagnosis in this analysis, these adverse consequences would be similar (though the cost 
of testing might be less), as neither IGRAs nor TST can distinguish LTBI from active TB 
disease. 
While IGRAs are commercially available and commonly used in the Indian private 
healthcare sector, research has revealed substantial confusion and inconsistency in the 
interpretation of IGRAs on the part of healthcare practitioners [30] .  A recent survey of 
Indian pulmonologists, ophthalmologists, and rheumatologists found that 91.9% of 
those surveyed reported using IGRAs “routinely” or “sometimes” in their practices.  This 
same survey found that, despite the widespread use of IGRAs among those surveyed,  
more than 80% of those surveyed believed that the test was able to differentiate 
between latent and active TB, and only 13% believed that the test was mainly intended 
for diagnosing latent, and not active, TB infection .  The main barrier to the use of IGRAs 




demonstrates, however, the major cost to the health system of IGRA testing for active 
TB results from the treatment of the substantial number of false-positive TB patients 
identified by IGRAs.   
In comparison, Xpert MTB/RIF identified a similar number of true positive TB 
cases as IGRAs (131,700 vs. 132,100), while making considerably fewer false-positive 
diagnoses (67,500 vs. 438,200).  These additional false positive diagnoses by IGRAs 
represent a misallocation of financial and human-resources, as well as added health 
risks for individuals wrongly undergoing treatment for active TB.  In addition to 
increased specificity and same-time drug sensitivity testing, Xpert MTB/RIF can provide 
TB results in as little as an hour, making same-day diagnosis and treatment initiation a 
possibility.  Another significant advantage of Xpert MTB/RIF is the ability to rapidly 
perform drug susceptibility testing.  While accounting for the expense associated with 
MDR treatment for drug resistant TB cases naturally increases the overall cost of the 
Xpert MTB/RIF scenario, appropriate, timely treatment of drug-resistant TB is likely cost-
saving in the long term through the prevention of secondary MDR TB transmission and a 
reduction in MDR TB-associated morbidity and mortality.  A recent model has explored 
the optimum implementation strategy to maximize the impact of Xpert MTB/RIF in India 
[35], and the price of this test has been reduced by nearly 50% in the private sector via 
an Initiative to Promote Affordable, Quality TB Tests (IPAQT), supported by the Clinton 
Health Access Initiative [36]. 
Our analysis has important limitations. By adopting a healthcare perspective, and 




erosion of trust in the healthcare system following misdiagnosis, we may underestimate 
the societal cost of false-positive TB diagnosis.  Thus, our estimates of cost-effectiveness 
may actually be biased in favor of IGRAs compared to a societal analysis.  Additionally, 
we used published data rather than empirical estimates for our parameter values, which 
often vary considerably and may not be fully generalizable to an Indian context.  
Nevertheless, our findings were robust to wide parameter variation in sensitivity 
analysis, and our estimates likely underestimate the cost of false-positive TB diagnosis in 
healthcare systems where treatment of TB is more costly than in India.  Finally, we 
adopted a simplified model structure that, for example, assumed most people who 
tested positive for TB completed a full course of treatment, and that providers used 
IGRA results to diagnose active disease, rather than LTBI.  This model therefore does not 
fully capture the complex dynamics of the system in which TB diagnosis is actually 
performed. 
Improved diagnostics are a critical tool to control TB worldwide, and IGRAs have 
an important role to play in the diagnosis of LTBI, particularly in low--risk settings. The 
2014 WHO guideline on management of LTBI suggests that either TST or an IGRA can be 
used to test for LTBI in high-income and upper middle-income countries with estimated 
TB incidence less than 100 per 100 000 [32].  The guideline recommends that IGRA 
should not replace TST in low-income and other middle-income countries [32]. 
However, in the setting of severely constrained resources for TB control, it is also 
important to deploy existing diagnostic tests in a manner that is both responsible and 




effective if restricted to select high-risk groups (e.g. child contacts of active TB cases, 
immunosuppressed populations) in whom test results might feasibly be linked to LTBI 
treatment, and for whom such treatment offers the greatest clinical benefit [32]. This 
analysis quantitatively demonstrates that, due to the potential for massive misdiagnosis 
of individuals with LTBI as active disease, the use of IGRAs to diagnose active TB in high-
burden settings is likely to result in tremendous wastage of vital resources, and at 
substantial loss of health, even relative to insensitive tools such as sputum smear 
microscopy. The Standards for TB Care in India explicitly discourage the use of IGRAs 
and TST for active TB diagnosis [13], but greater efforts are necessary to raise awareness 
about this recommendation among Indian clinicians and laboratorians, and to redirect 
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Figure 3.1: Decision Analytic Model for IGRA Testing for Active TB in India 
A simplified schematic of the decision analytic model of one million TB suspects in India, with branches for the reference scenario 
(clinical exam only, no microbiological testing), reference scenario + testing with interferon-gamma release assays (“IGRA”), clinical 
exam + sputum smear microscopy (“Sputum Smear”), and clinical exam + testing with Xpert MTB/Rif with MDR treatment (“Xpert 
MTB/RIF”).  Differential infectiousness (as denoted by smear status, in the event that a smear could be performed) is incorporated 












* “Costs” includes the cost of empiric treatment and the cost of the reference test(s), as well as the cost of the microbiological 
testing and TB treatment (if applicable).  The “Xpert MTB/RIF” also includes the cost of MDR-TB treatment.  Consequences include 












TB Dynamics    
Probability of death, untreated smear-positive TB¹ 0.70 0.50-0.95 [37]  
Probability of death, untreated smear-negative TB 0.20 0.15-0.25 [37] 
Secondary TB infections per year, smear-positive TB 10 8-12 [38]  
Relative infectiousness of smear-negative TB 0.22 0.16-0.28 [39]  
Fraction of new TB cases that are smear-positive 0.53 0.40-0.66 [37]  
Characteristics of TB diagnosis    
Prevalence of active TB among persons with 
suspected active TB 
0.14 0.11-0.18 [40]  
Sensitivity for TB    
     Clinician diagnosis² 0.53 0.40-0.67 [31]  
     Sputum smear microscopy 0.53 0.34-0.65 [41] 
     IGRA³ (QuantiFERON-TB Gold) 0.84 0.56-0.96 [4]  
     Xpert MTB/RIF⁴ (smear-positive TB) 0.98 0.97-0.99 [18]  
     Xpert MTB/RIF (smear-negative TB) 0.67 0.58-0.74 [18]  
Specificity for active TB⁵    
     Clinician diagnosis 0.94 0.75-1.00 [42]  
     Sputum smear microscopy (two smears) 0.97 0.75-1.00 [43] 
     Xpert MTB/RIF 0.98 0.97-0.99 [18] 
     IGRA (QuantiFERON-TB Gold) 0.52 0.41-0.62 [4]  
Xpert MTB/RIF Rif resistance    
     Sensitivity 0.94 0.87-0.97 [18]  
     Specificity 0.98 0.97-0.99 [18]  
Time to TB diagnosis (days)    
     Sputum smear microscopy 7 2.92-14.05 [44,45]  
     GeneXpert MTB/RIF 7 0.50-14.05  
     IGRA (QuantiFERON-TB Gold) 7 2.92-14.05  
Loss to follow-up    
     Sputum smear microscopy 0.15 0.11-0.19 [46,47]  
     Xpert MTB/RIF 0.15 0.11-0.19  
     IGRA (QuantiFERON-TB Gold) 0.15 0.11-0.19 [17] 
Characteristics of TB treatment    
Proportion of treated TB patients who die 0.045 0.033-0.056 [31]  
Proportion of treated HIV⁶/TB patients who die 0.090 0.068-0.114 [31]  
Proportion of treated TB patients infections at 1 
year 
0.045 0.033-0.056 [31]  
HIV/TB    
HIV prevalence, general population 0.3% 0.225-0.4% [48]  
HIV prevalence, patients with TB 5.3% 4.0-6.6% [31]  
Proportion of HIV-infected patients with ART⁷ 
access 
0.10 0.075-0.125 [48]  




Unit cost, independent laboratory    
     Sputum smear microscopy (two smears) $3.00 $1-$5 [24,49]  
     Xpert MTB/RIF $25 $20-$57 [50]  
     IGRA (QuantiFERON®-TB Gold) $30 $15-$50 [27,30]  
Mean cost of treating one case of drug-susceptible 
TB 
$66.00 $50-$75 [31]  
Mean cost of treating one case of MDR⁸ TB $2600 $500-$5500 [31]  
DALY⁹ weights    
      Active TB 0.264 0.198-0.330 [51]  
     TB treatment 0.132 0.099-0.165 [17]  
Life expectancy after TB cure (years) 40 30-50 [52,53]  
1 TB, Tuberculosis 
2 In the absence of any TB-specific microbiological test 
3 IGRA, Interferon-Gamma Release Assay 
4 MTB/RIF, Mycobacterium tuberculosis and Rifampin Resistance Testing 
5 Excludes studies not performed in developing countries 
6 HIV, Human Immunodeficiency Virus 
7 ART, antiretroviral therapy 
8 MDR, Multi-drug resistant 


















Figure 3.2: Economic and epidemiological outcomes among 1 million adults with TB 
symptoms in India 
Model outcomes, including true positive TB cases treated, false positive cases treated, 
incremental DALYs averted, and costs (in 2013 US dollars) are presented below for each 
diagnostic strategy evaluated in the decision-analytic model. 
1  Compared to the reference scenario 
2  Costs are in 2013 US Dollars/100 
3 The reference scenario consists of clinical examination only, including chest X-Rays, physical 
exam, etc.  No microbiological testing is considered in the reference scenario 
4 Interferon Gamma Release Assays 
5 Sputum smear microscopy 







Figure 3.3: One-Way and Two-Way Sensitivity Analyses on Parameters Affecting Cost 
and DALYs Averted 
Top) Tornado diagram examining model parameters with the largest impact on the cost of the 
IGRA testing strategy. Bottom) Tornado diagram examing model parameters with the highest 











Figure 3.4: Select Two-Way Sensitivity Analyses 
Left) Two-way sensitivity analysis of the effects of changes in IGRA sensitivity and specificity parameters within pre-specified ranges on DALYs 
averted, demostrating the most effective diagnostic strategy, irrespective of cost.  Right) Two-way sensitivity analysis of the effects of changes in 
IGRA and Xpert MTB/Rif prices within pre-specified ranges on the cost of each diagnostic approach, demostrating the least costly diagnostic 






S1 File: TreeAge Decision-Analytic Model for IGRA Cost-Effectiveness Analysis in India 
This TreeAge .trex file contains the full model and all parameters used for this analysis. 
 






S2 File: TreeAge Probabilistic Sensitivity Analysis for IGRA Cost-Effectiveness Analysis 
in India 
This TreeAge .trex file contains the full model and all parameters used in the 
probabilistic sensitivity analysis. 
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PREDICTORS OF ISONIAZID PREVENTIVE THERAPY COMPLETION AMONG 


















CHAPTER 4 INTRODUCTION 
 
While Chapters 2 and 3 explored TB case finding and the diagnosis or exclusion of TB 
disease through accurate diagnostics, respectively, TB can also prevented or treated 
through the use of appropriate therapy.  Chapter 4 explores the prevention portion of 
the TB case-finding and prevention pathway by looking at the use of isoniazid preventive 
therapy (IPT) in newly diagnosed HIV patients in rural Malawi.  While IPT has been 
shown to effectively prevent TB reactivation in people living with HIV (PLHIV), 
preventive therapy has not been widely implemented.  Even among those who receive 
IPT, the preventive therapy is only maximally effective for individuals who complete at 
least 6 months of treatment.  Identification of high-risk individuals (who could benefit 
from additional support during the therapy period) may help to ensure that all PLHIV 
initiating IPT accrue the maximum value of the treatment.   Boosting IPT completion 
rates among PLHIV may reduce TB-related morbidity and mortality.  It may also benefit 
the larger community by preventing additional secondary disease transmission and 
reducing healthcare-associated spending.  To inform potential interventions to 
encourage IPT completion, we sought to identify predictors of IPT-completion (and non-










Background:  To reduce the risk of TB among people living with HIV (PLHIV), WHO 
recommends receipt of at least 6 months of isoniazid preventive therapy (IPT) once 
tuberculosis (TB) disease has been excluded.  However, completion of IPT remains a 
major challenge in resource-limited settings.    
 
Methods: We evaluated predictors of IPT completion (defined as ≥150 daily doses) in 
newly diagnosed PLHIV recruited from eight rural primary clinics in Malawi, as part of a 
cluster-randomized trial of TB screening.  Predictors of IPT completion were evaluated 
using a multilevel logistic regression model adjusted for patient characteristics, and 
random-effects term to account for clustering by clinic. 
 
Results: 974 participants screened negative for active TB and were started on IPT.  
Overall, 732 (75%) completed ≥150 doses, although 8% of individuals experienced 
treatment interruptions of at least 2 months.  After controlling for potential 
confounders, participants younger than 25 years (compared to those over 45 years, 
aOR: 0.33, 95% CI: 0.18-0.60) and males (compared to non-pregnant women, aOR: 0.57, 
95% CI: 0.37-0.88) had significantly lower odds of IPT completion.  Concomitant receipt 
of ART, alcohol use, or smoking status were not significantly associated with odds of IPT 




Conclusions:  We found that IPT screening and provision at the time of an initial HIV 
diagnosis was acceptable in rural Malawi.  In our population of adults newly diagnosed 
with HIV, three-quarters of those who initiated preventive therapy successfully 
completed six months of IPT.  We observed lower odds of completion among men and 
participants younger than the age of 25.  Additional efforts may be needed to ensure IPT 




















Tuberculosis (TB) remains a leading cause of death among people living with HIV 
(PLHIV) worldwide [1].  While antiretroviral therapy (ART) reduces the risk of developing 
TB disease among HIV-infected individuals through reconstitution of the immune 
system, the risk of TB activation is still higher among PLHIV than amongst their HIV-
uninfected counterparts, especially in the first six months of ART [2].  Treatment with 
isoniazid preventive therapy (IPT) has been shown to prevent TB disease in PLHIV above 
and beyond the effects of ART alone, and has also demonstrated a synergistic effect 
when administered concomitantly with ART [3,4].  
Despite longstanding recommendations from the World Health Organization 
(WHO) that 6 months of IPT should be offered to all PLHIV in which active TB disease is 
not suspected, global IPT coverage remains low [5].  It is estimated that only 25% of the 
IPT-eligible individuals in care for their HIV are currently receiving IPT [6].  The time of 
initial HIV diagnosis represents a frequently missed opportunity to screen individuals for 
TB and initiate IPT.  Once IPT is initiated, PLHIV also face barriers to treatment 
completion, including stigma, fear of side effects, poor relationships with healthcare 
providers, transport costs for medication refills, and the challenge of taking medication 
in the absence of symptoms [7,8].  As global efforts to scale-up IPT coverage continue, 
strategies to increase treatment adherence and boost rates of IPT completion are 





Providing IPT soon after an HIV diagnosis targets those individuals at highest risk 
of TB disease (who therefore stand to benefit the most from IPT) and is achievable in 
routine clinical settings. Identifying those individuals at greatest risk of non-adherence 
in this setting could inform targeted strategies to provide additional support during 
treatment, which in turn may boost completion rates and reduce incident TB in this 
population.  While a small number of studies have evaluated predictors of IPT 
adherence in South Africa [7,9,10], few studies have looked at such predictors in a low-
income setting, in the context of providing IPT soon after the first HIV diagnosis.  In an 
effort to inform strategies to improve IPT adherence, we sought to identify predictors of 
IPT completion among a cohort of recently diagnosed HIV patients in Malawi, a high 





This analysis is nested in a larger randomized clinical trial of TB diagnosis among 
newly diagnosed PLHIV in rural Malawi (CHEPETSA, clinicaltrials.gov #NCT01450085).  
Twelve clinics were randomized in three phases (four clinics each) to one of two TB 
screening algorithms, namely symptom screening plus sputum smear microscopy and 
symptom screening plus Xpert MTB/RIF (Cepheid, Inc.; Sunnyvale, CA).  Individuals in 
whom active TB disease was excluded were prescribed six months of IPT.  Data for this 




2014, and comprise PLHIV from the eight clinics participating in the first two phases of 
the trial. 
Participants were eligible for the study if they were ≥18 years of age, were not 
taking IPT, on TB treatment, or receiving antiretroviral therapy (ART) in the study clinic 
at enrollment.   Participants were not eligible to participate if they were unable to speak 
English or Chichewa, had language and/or hearing impairments, were a prisoner, or 
were unwilling or unable to give informed consent.  All participants underwent TB 
symptom screening, and those who reported one or more TB symptoms received 
microbiological testing at the point of care, on the day of diagnosis (performed by 
nurses or clinical staff), using either sputum smear microscopy with light-emitting diode 
(LED) fluorescence microscopy or Xpert MTB/RIF (Cepheid, Inc, Sunnyvale, CA, USA).   
All participants in whom active TB disease had been excluded (either through 
symptom screening and/or microbiological testing) were screened for IPT eligibility 
according to routine program criteria [12].  Symptomatic participants in who tested 
negative for TB disease became eligible for IPT if/when their symptoms resolved, which 
was determined during subsequent monthly follow-up visits.  Participants who had 
known liver disease, reported excessive alcohol consumption (2 or more times per 
week, or 3 or more drinks per typical drinking day), or had a history of epilepsy, kidney 
failure, or severe peripheral neuropathy were considered ineligible; all others were 
offered IPT.  Eligible participants were prescribed six months of IPT, dispensed in 
monthly or semi-monthly intervals during routine clinic visits.  The number of pills 




adherence.  ART was initiated after enrollment per the Malawian Ministry of Health’s 
contemporary HIV guidelines [12]; eligibility for ART included WHO Stage 3 or 4 disease, 
CD4+ T-cell count <350 cells/mm3, or pregnancy/breastfeeding. 
 
Study Procedures 
Participants were followed-up during routine visits for HIV-related care every 1-3 
months, until one year of follow-up was attained.  Study participants who were eligible 
for IPT were offered 300 mg of isoniazid daily, as well as 25 mg of pyridoxine daily, for 
six months.  Up to 180 doses of IPT in total were dispensed during routine clinical visits, 
the timing of which was determined by routine clinical guidelines and follow-up 
appointments, and was not dictated by the study.   
Participants receiving IPT also underwent safety monitoring by study nurses to 
track potential hepatotoxicity, peripheral neuropathy, and other adverse reactions per 
local guidelines and practice [12].  Before initiating IPT, participants received routine 
counseling regarding the potential side effects of isoniazid, and were advised to seek 
treatment immediately if they experienced any of those symptoms.  Individuals 
reporting symptoms of hepatotoxicity underwent blood draws to test bilirubin and 
transaminase levels.   
Participants completed a demographic and clinical history questionnaire at 
baseline, as well as at each follow-up visit.  Questionnaires were completed by trained 
study staff, and included questions about TB symptoms, possible IPT-related adverse 




Tuberculosis symptoms included the presence of one or more of the following: cough, 
fever, night sweats, or weight loss.  The presence of TB symptoms was assessed at 
enrollment and at each subsequent follow-up visit.   
 
Statistical Methods 
Our primary outcome was completion of IPT, which was defined as receipt of ≥ 
150 doses of isoniazid, as documented in the participant’s study file.  Non-completion 
was defined receiving less than 150 doses of IPT, reasons for which included loss to 
follow-up, death, IPT cessation by healthcare provider, refusal to continue IPT, reported 
IPT side effects, incident TB diagnosis, or transfer to another clinic.  We examined 
univariate associations with IPT completion using chi-square or Fisher’s exact tests and 
Wilcoxon-Mann-Whitney tests.  We constructed a multilevel logistic regression model to 
explore the relationship between IPT completion and individual-level and clinic-level 
predictors including concomitant receipt of ART, age, pregnancy status, IPT side-effects, 
and alcohol use.  Concomitant ART exposure was defined as any self-reported receipt of 
ART drugs beginning either before, or within 7 days after, IPT initiation.  We 
incorporated a random effects term to account for clustering at the clinic level.  
Variables that reached a significance of p<0.1 in the univariate analysis, or that were 
considered to be of epidemiological significance a priori, were considered for the 
multivariate model.  Additionally we performed a time-to-non-completion survival 
analysis, stratified by key exposure variables identified in the analysis above.  Time to 




where the participant received his/her last IPT dosages.  All analyses were performed in 
Stata 12 (Stata Corp., College Station, USA).   
 
Ethical Considerations 
This study was approved by the Malawi University College of Medicine Research 
Ethics Committee and the Johns Hopkins University School of Medicine Institutional 
Review Board.  All study participants provided individual written informed consent 




A total of 1,359 participants were enrolled (Figure 4.1) across 8 study clinics, for 
an average of 122 participants per clinic (range: 47-199) (data not shown).   During 
screening, 504 (37%) participants reported one or more symptoms of TB (cough, fever, 
night sweats and/or weight loss) and received microbiological testing for active TB 
disease with either sputum smear microscopy or Xpert MTB/RIF.  Of those tested, 27 
(5%) had active TB and were thus ineligible for IPT.  Of the 477 symptomatic individuals 
testing negative for TB disease, 253 (53%) returned for IPT eligibility screening.  
Altogether 1,106 participants were screened for IPT eligibility either at ART initiation or 
a subsequent visit (253 symptomatic TB-negative participants, and 853 asymptomatic 
participants).  Of these, 95 (9%) failed to meet the IPT eligibility criteria, and 984 (89%) 




(0.09%) IPT-eligible individual in our study refused to initiate preventive therapy.  Ten 
participants were subsequently excluded from this analysis because they were missing 
IPT outcome data. 
Participants in our study were majority female (n=650, 67%) and had a median 
age of 33 (interquartile range [IQR]: 27-40) (Table 4.1).  Male participants were 
significantly older than their female counterparts (38.1 vs. 32.4 years, p<0.001) (data 
not shown).  Most participants reported being in “Good” or “Fair” health at enrollment 
(n=788, 81%), and were classified as WHO HIV Stage I or II (n=794, 82%) at the time of 
their HIV diagnosis. Individuals in our sample completed a median of 6 (IQR: 4-7) routine 
clinical follow-up visits during the study period.   Concomitant ART exposure was 
relatively uncommon in our cohort (n=152, 16%), though the majority of participants 
reported initiating ART at some point during the IPT treatment period (n=670, 69%).  
Among those initiating IPT, the most (n=770, 79%) reported never drinking.  Both 
smoking (39% vs. 4%, p<0.001) and alcohol use (51% versus 6%, p<0.001) were 
significantly more common among men than women in our study population (data not 
shown).  IPT interruptions were relatively uncommon during the study; approximately 
8% (n=82) of the sample experienced an interruption in treatment of 2 months or more. 
The majority of participants initiating IPT completed treatment (n=732, 75%), 
though completion rates varied significantly across the 8 study sites (range: 57-90%, p < 
0.001) (data not shown).  Most non-completers stopped IPT due to treatment 
cessation/failure to return for follow-up (n=198, 82%), but other reasons for non-




(n=10, 4%), refusal to continue treatment (n=7, 3%), side effects of treatment (n=6, 2%), 
incident TB disease (n=2, 1%), or a healthcare provider’s decision to stop treatment 
(n=1, 0.4%).  Individuals completing IPT received a median of 177 doses (IQR: 167-200), 
while non-completers stopped treatment after a median of 58 doses (IQR: 28-139). 
Compared to non-completers, those who completed IPT were older (median age 
34 vs. 31 years, p<0.001), had completed more follow-up visits (median 6 vs. 1, 
p<0.001), and were less likely to have experienced a prolonged treatment interruption 
(7% vs. 13%, p=0.01).  IPT completers did not differ from non-completers in terms of 
self-reported general health, WHO HIV stage, or the presence of TB symptoms at 
enrollment.  Rates of completion were highest among non-pregnant women above the 
age of 25 (82%, 95% CI: 78-86%), and lowest among young, non-pregnant women (63%, 
95% CI: 53-73%) and young pregnant women (64%, 95% CI: 54-74%) (Figure 4.2).   
 
Multilevel Model & Survival Analysis 
After multivariate adjustment, age less than 25 (compared to age > 45, aOR: 
0.33, 95% CI: 0.18-0.60) and male sex (compared to non-pregnant females: aOR: 0.57, 
95% CI: 0.37-0.88) were significantly associated with worse IPT completion rates (Table 
4.2).  Though it did not reach statistical significance after adjustment, pregnant women 
had lower odds of IPT completion than non-pregnant women (aOR: 0.83, 95% CI: 0.55-
1.27).  Despite the fact that younger age appeared to reduce the rate of IPT completion 
among both pregnant and non-pregnant women more than it did among men, we did 




shown).  Concomitant exposure to ART, self-reported alcohol use, being a current or 
former smoker, or reporting any TB symptoms at baseline were not significantly 
associated with IPT completion in our model.  Survival analysis of time-to-IPT-non-
completion illustrates the higher probability of treatment non-completion among 
participants younger than 25 years of age compared to their older counterparts (Figure 




We found high rates of IPT completion in this cohort of newly diagnosed PLHIV in 
rural Malawi.  Our results indicate that IPT completion among newly diagnosed PLHIV 
can be reasonably high even under operational conditions in rural, low-income settings.  
Given that over 99% of the IPT-eligible participants in our study initiated preventive 
therapy, it appears that IPT eligibility screening at the time of an initial HIV diagnosis is 
acceptable to patients in this setting.  In our study population older age and being a 
non-pregnant female significantly increased the odds of IPT completion.  While 
concomitant receipt of ART was not significantly associated with increased odds of IPT 
completion, most of our study participants did initiate ART during the preventive 
treatment period.  Our findings suggest that point-of-HIV-diagnosis TB screening and IPT 
initiation may be an effective strategy to reduce the TB burden in newly diagnosed 





Our findings are supported by other findings from the published literature.  
Earlier studies conducted in high TB/HIV burden settings [13–17] have found similarly 
high rates of IPT completion.  A previous meta-analysis on interventions to improve IPT 
adherence also suggests that TB/HIV integration may boost IPT completion rates [18].  
These findings further support our conclusion that the initial HIV diagnosis represents an 
opportunity to screen HIV-infected individuals for TB and (for those who are eligible) to 
initiate IPT, as well as an effective strategy for further integration of HIV/TB programs.   
While overall IPT completion was high in our study, several sub-groups had 
significantly lower rates.  We found that individuals who were younger than 25 were 
significantly less likely to complete IPT than their older counterparts.  Previous work 
from Tanzania [16] and Uganda [19] also found that younger age was associated with an 
increased risk of treatment non-completion among HIV-infected individuals on IPT, 
however, the reasons for this are unclear.  Younger participants in our study tended to 
be healthier at baseline, and were less likely to have initiated ART during follow-up, 
potentially making it harder to adhere to IPT in the absence of any symptoms [7], or 
with the support of ongoing clinic visits to obtain antiretroviral drugs.  A better 
understanding of the particular barriers to preventive treatment completion faced by 
young HIV-infected individuals is still needed, as are evidence-based interventions to 
address them.   
While the IPT completion rates among pregnant women observed in this study 
were similar to rates observed in other studies conducted in low-resource settings [20], 




antenatal care still had decreased odds of IPT completion (though this did not reach 
statistical significance after adjustment).  WHO guidelines for the treatment of 
tuberculosis recommend the integration of TB prevention and treatment into existing 
antenatal care and prevention of mother-to-child HIV transmission programs [21].  
However, integration remains a challenge in many settings, and results in low rates of 
IPT initiation among pregnant women [22,23].  Compared to non-pregnant women, men 
also had significantly lower rates of IPT completion in our study. 
Unlike previous studies, we did not find a significant relationship between 
alcohol or tobacco use and IPT completion [14].  Both current/former smoking and any 
alcohol use were associated with small, non-significant reductions in the odds of IPT 
completion.    It is possible that we did not observe a negative relationship between 
alcohol use and IPT completion given that moderate to heavy drinkers were not eligible 
for IPT in our study.  Alternatively, alcohol and tobacco use may be weaker indicators of 
individuals who will have difficulty with treatment adherence in a rural, low income area 
than in other settings.   
As with any observational study, this research has certain limitations. 
Measurement of IPT completion status was based on the number of IPT doses 
dispensed during routine study visits rather than any objective measure (e.g., urine 
metabolites).  Nevertheless, self-reported and/or pill count adherence correlates 
reasonably well with other measures of adherence [25–27], and from a pragmatic 
perspective, it is unlikely that adherence will be measured in any other fashion in the 




accessible, we were unable to measure all potential predictors of adherence, including 
clinic-level variables that appeared to have strong influence. Future research could more 
fully evaluate a wider range of associations with IPT adherence, and could also consider 
study of potential interventions to improve adherence in those at greatest risk of non-
completion.   
In conclusion, we found that – in this population of over 1,000 rural Malawian 
adults who were routinely screened for TB soon after a new HIV diagnosis – completion 
of preventive therapy for tuberculosis was high.  These findings support the use of 
point-of-HIV-diagnosis screening for active TB, followed by immediate IPT initiation for 
eligible individuals.  Our observed predictors of IPT non-completion highlight the 
importance of additional efforts to support younger patients and men.  Ultimately, 
stronger systems to provide IPT at the point of HIV diagnosis, coupled with research to 
identify and overcome barriers faced by populations at high risk of non-completion, can 


































*224 individuals who had TB symptoms at enrollment and received microbiological testing for TB disease were not 





Table 4.1: Patient-level clinical and demographic characteristics, by IPT completion 
status 
 
 † P-value obtained from a two sample Wilcoxon rank-sum test 
 ‡ P-value obtained from a Fisher’s exact test 
* 7 individuals were missing WHO stage classification 











N (%) N (%) N (%) 
Age Category     
18-25 132 (18.0) 72 (29.8) 204 (20.9) 
0.001 
26-35 296 (40.4) 87 (36.0) 383 (39.3) 
36-45 204 (27.9) 58 (24.0) 262 (26.9) 
>45 100 (13.7) 25 (10.3) 125 (12.8) 
Sex/Pregnancy Status     
Pregnant female 151 (20.6) 60 (28.4) 211 (21.7) 
0.133 Non-pregnant female 343 (46.9) 96 (39.7) 439 (45.1) 
Male 238 (32.5) 86 (35.5) 324 (33.3) 
Self-Reported Health     
Excellent 100 (13.7) 31 (12.8) 131 (13.5) 
0.827 
Good 368 (50.3) 125 (51.7) 493 (50.6) 
Fair 225 (30.7) 70 (28.9) 295 (30.3) 
Poor 39 (5.3) 16 (6.6) 55 (5.7) 
WHO HIV Stage*     
1 or 2 599 (82.4) 195 (81.3) 794 (82.1) 
0.689 
3 or 4 128 (17.6) 45 (18.8) 173 (17.9) 
Previous History of TB 10 (1.4) 3 (1.2) 13 (1.3) 1.0‡ 
Any TB Symptoms at Enrollment 164 (22.4) 40 (16.5) 204 (20.9) 0.052 
Concurrent ART Exposure 122 (16.7) 30 (12.4) 152 (15.6) 0.113 
Eligible for ART at Enrollment 355 (48.8) 117 (48.8) 472 (48.8) 0.983 
Number of Follow-Up Visits 
(Median, IQR) 
6 (5-7) 1 (0-3) 6 (4-7) <0.001 
Experienced IPT Side-Effects 
during Follow-Up 
6 (0.8) 3 (1.7) 9 (1.0) 0.389‡ 
Hospitalized during Follow-Up 36 (4.9) 7 (3.9) 43 (4.7) 0.696‡ 
Experienced an IPT interruption 
of >2 months 
52 (7.1) 30 (12.5) 82 (8.4) 0.010 
Current/Former Smoker 112 (15.3) 42 (17.4) 154 (15.8) 0.448 




Figure 4.2: IPT Completion Rates by Age Category and Sex/Pregnancy Status 
 
 
Error bars indicate 95% Confidence Intervals around estimates.  Isoniazid Preventive Therapy (IPT) completion was 






Figure 4.3: IPT Non-Completion Survival Curve, Time to non-completion of Isoniazid 














Shown are the Kaplan-Meier curves describing the time from IPT initiation to the date at which the 
participant either completed IPT (received the last dose), or was censored (due to treatment default, death 
, refusal of further treatment, IPT stopped by doctor, side effects, TB diagnosis, or transfer out of the clinic 







Table 4.2: Univariate and Multivariate Models for IPT Completion* 
 
*Multilevel logistic models of IPT completion with clinic-level random intercept 
** Model adjusted for age (over/under 25 years), sex/pregnancy status, the presence of TB 






OR 95% CI aOR 95% CI 
Age Category     
18-25 0.37 (0.21-0.64) 0.33 (0.18-0.60) 
26-35 0.80 (0.48-1.35) 0.78 (0.46-1.33) 
36-45 0.84 (0.49-1.45) 0.85 (0.49-1.47) 
>45 Ref Ref Ref Ref 
Sex/Pregnancy Status     
Female, not pregnant Ref Ref Ref Ref 
Female, pregnant 0.66 (0.44-0.98) 0.86 (0.56-1.31) 
Male 0.69 (0.49-0.99) 0.57 (0.37-0.88) 
Any TB Symptoms at Enrollment 1.25 (0.82-1.89) 1.09 (0.55-2.19) 
Concurrent ART Exposure 1.27 (0.80-2.00) 1.08 (0.70-1.72) 
Experienced an IPT Interruption of 
>2 months 
0.53 (0.32-0.88) -- -- 
Any Alcohol Use 0.96 (0.67-1.39) 1.09 (0.70-1.72) 
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SUMMARY OF RESULTS: 
 
Meeting ambitious global TB control goals, especially in high-burden settings, 
will require efficient, effective interventions targeting each stage of the TB case-finding 
and prevention pathway.  The impact and relative cost-effectiveness of these 
interventions in a given location, however, will depend on a number of setting-specific 
factors including patient and community resources, awareness and concern over TB, 
underlying risk of TB acquisition and progression, transportation cost and availability, 
cost and availability of healthcare, TB/HIV-related stigma, among other factors.  
Research to identify context-specific barriers, and efficient TB-control interventions that 
take them into account, is vital to further reductions in TB related morbidity and 
mortality.   
Our research found that active contact tracing—specifically household contact 
tracing—for TB was feasibly implemented in a rural South African setting.  Our 
household contact tracing intervention found a high proportion of previously 
undiagnosed TB among household contacts (household prevalence: 3.9% (95% CI: 2.0-
6.9%)) and a yield of 8.5 (95% CI: 4.2-15.1) new TB cases per 100 index cases traced.  
These findings were qualitatively comparable to the findings of a similarly-structured 
intervention carried out in Klerksdorp, an urban/peri-urban area in South Africa with a 
much higher population-level prevalence of TB [1].  
The majority of household contacts with previously undiagnosed TB disease 




asymptomatic.  In our multivariable, multilevel logistic regression model, factors 
significantly associated with active TB among household contacts included living in a 
female-headed household (aOR: 5.19, 95% CI: 1.06-25.44), and having more than a high 
school education (aOR: 6.88, 95% CI: 1.19-39.66).  Female sex, age, household income, 
employment status, and symptom duration were not significantly associated with 
increased odds of previously undiagnosed TB among household contacts. 
Accurate identification of TB cases through diagnostic testing of TB suspects is 
the next step on the TB case-finding and prevention pathway.  For Aim 2 we evaluated 
the incremental cost-effectiveness of a base-case scenario of empirical diagnosis (with 
no microbiological testing) to scenarios in which this base-case was augmented by the 
addition of either sputum smear microscopy, Xpert testing (with and without the 
additional cost of treating drug resistant TB cases identified by this test), and interferon-
γ release assays (IGRAs).  We evaluated the cost-effectiveness of IGRAs from the 
perspective of the Indian TB control sector in a hypothetical cohort of 1 million adult 
Indian TB suspects.   
Because of IGRAs’ poor specificity for active TB in settings with high background 
rates of latent TB infection (LTBI), the use of IGRAs in an Indian context would result in 
tremendous over-diagnosis of active TB.  In fact, the use of IGRAs in a setting like India 
would result in approximately 3 additional false-positive active TB diagnoses for every 
additional individual correctly diagnosed.  We estimated that, relative to sputum smear 
microscopy, the use of IGRAs this hypothetical cohort of Indian TB suspects would 




million in additional healthcare expenditures for every million patients tested in this 
fashion.  Over 40% of the incremental cost of IGRAs compared to smear would be due to 
the expense of unnecessarily treating individuals with LTBI for active TB disease.  This 
amount dwarfs the estimated US$7.6 million it would cost to treat all individuals in the 
cohort for multidrug resistant TB (MDR-TB), an expense that the Indian TB control 
program in the past has argued is unsupportable.  
Once a diagnosis of active TB has been made or excluded, the next step of the 
pathway is appropriate preventive or curative treatment.  For individuals at high risk of 
TB, such as people living with HIV (PLHIV), if active TB is not suspected, six months of 
treatment with isoniazid preventive therapy (IPT) is recommended [2].  While coverage 
rates remain low globally [3], IPT has been shown to reduce the risk of TB reactivation in 
PLHIV, above and beyond the effects of antiretroviral therapy (ART) alone, and can be 
effective in preventing TB disease in the high-risk months immediately before and after 
ART initiation [4,5].  For individuals who do begin IPT, treatment completion can be 
hindered by a number of factors, including distance to health facility, HIV and TB stigma, 
and transport costs (among others) [6–9].   
For Aim 3 we explored predictors of IPT completion among adults newly 
diagnosed with HIV in rural Malawi in the hopes of identifying sub-populations at risk of 
treatment non-completion who may benefit from added support during IPT.  Of the 973 
participants who started IPT (and in whom active TB disease had been excluded), just 
over 75% completed their course of treatment (732/973), defined as receipt of ≥150 




for clinic-level clustering, male sex (compared to non-pregnant females, aOR: 0.57, 95% 
CI: 0.37-0.88) and age less than 25 (compared to age >45, aOR: 0.33, 95% CI: 0.18-0.60) 
were associated with reduced odds of IPT completion in this population of newly 
diagnosed adult PLHIV in rural Malawi.  Though it was not statistically significant, 
pregnant women had lower odds of IPT completion than non-pregnant women in our 
study (aOR: 0.86, 95% CI: 0.56-1.31).  Concomitant receipt of ART, the presence of self-
reported TB symptoms, alcohol use, and smoking status were not significantly 
associated with IPT completion in our model. 
 
STRENGTHS AND LIMITATIONS: 
 
These analyses were subject to a number of important limitations.  As a pilot 
study, the household contact tracing intervention (in Aim 1) included a relatively small 
sample size (130 households comprising 282 household contacts), which limited our 
power and ability to identify important differences between household contacts with 
and without active TB disease.  Low clinic volumes, large distances between clinics, a 
small study team, and difficult road conditions meant that recruitment proceeded more 
slowly than expected. (Approximately 13 index cases and 28 household contacts were 
recruited per study month.)  While this was an important finding in terms of the 
feasibility and challenges associated with implementing a similar intervention in this 
context, these barriers resulted in a smaller overall sample size than originally intended.  




than via rapid tests performed during the household visits.  Self-reported HIV status 
likely underestimates the true prevalence of HIV among household contacts, which is 
problematic given the strong association between HIV status and TB disease.  Future 
research will include point-of-contact HIV testing during household tracing visits to 
better assess the acceptability, yield, and cost-effectiveness of this approach.   
Finally, for purposes of comparability to a similarly-designed contact tracing 
intervention conducted in a high TB burden urban/peri-urban in South Africa [1], we 
diagnosed individuals with active TB based on sputum smear microscopy and culture 
results.  While the more sensitive culture testing proved necessary to identify smear-
negative/culture-positive cases of TB in our study population, this TB diagnostic can take 
4-6 weeks for results to be made available, does not provide same-time drug sensitivity 
results, and (at least in our setting) resulted in a relatively high number of non-
tuberculosis mycobacterium infections that tested culture positive and required 
speciation.  Future research will consider the cost-effectiveness of more rapid and 
sensitive diagnostic options such as Xpert MTB/RIF (a sputum-based molecular test for 
TB that can yield results in as little as two hours).   
When comparing the cost-effectiveness of several microbiological tests for TB in 
a hypothetical cohort of Indian adult TB suspects (in Aim 2), we did so from the 
perspective of the Indian healthcare sector, rather than a societal perspective.  Analysis 
from a societal perspective would have accounted for transport, TB testing, and TB 
treatment costs that are borne by patients and their families.  This would include the 




in favor of IGRAs by underestimating the societal costs of false-positive diagnoses.  
Because IGRAs are most commonly used in the Indian private sector, where patients 
(and not the TB control program) bear the testing and treatment costs, the use of an 
expensive diagnostic with a low specificity is particularly problematic.  In performing this 
analysis we constructed a relatively simple model that did not include a number of 
factors that might influence the cost-effectiveness of TB diagnostics as used in the real 
world.  For example, we did not explore the impact of LTBI, or the use of IGRAs to 
diagnosed LTBI, and we assumed that individuals who initiated treatment completed 
their treatment.   
Additionally, the data used to inform our model were based on published 
estimates, which may not completely represent true parameter values in an Indian 
context.  The model may be biased if the parameter values used to populate it are 
themselves biased, which is a known limitation of cost-effectiveness analysis more 
generally.  Finally, because India’s TB epidemic is not driven by a high prevalence of HIV 
infection, these results may not be generalizable to other high TB-burden settings (such 
as sub-Saharan Africa), where rates of HIV are higher, or the use of IGRAs may be less 
widespread.     
 When evaluating predictors of IPT completion among a cohort of newly 
diagnosed people living with HIV (PLHIV) in rural Malawi, our outcome (IPT completion) 
was defined as the receipt of ≥150 doses of IPT at the clinic.  We were unable to include 
a more objective measure of adherence, such as isoniazid urine metabolites [10], and 




While previous studies have found reasonable correlation between the number of pills 
dispensed, patient self-report, and other objective measures of adherence [11–13], it is 
possible that we over-estimated the proportion of individuals completing IPT in our 
study.  We collected information on a number of self-reported patient demographic and 
clinical characteristics, but we may have omitted important predictors of IPT 
completion.  We did not have information on participant SES, distance from the health 
facility, cost of transport from their home to the health facility, knowledge and beliefs 
about TB, TB/HIV stigma, or perceived barriers to treatment completion.  These factors 
(and others) may play important roles in the likelihood of treatment completion for 
PLHIV in this setting, and should be explored further in future research.  Clinic level 
factors, such as size, patient volume, wait times, staff/patient relations, and facility 




PUBLIC HEALTH IMPORTANCE: 
 
Analysis of the impact and potential cost-effectiveness of interventions targeting 
three different stages of the TB case-finding and prevention pathway may provide 
additional data for decision makers in rural, high TB burden settings.  For Aim 1, our 
findings suggest that high yields may be obtained from contact tracing, even in settings 
of moderate background TB transmission, and that household may be an important site 




diagnosed with TB disease in our study were culture positive/smear negative, suggesting 
that household contact tracing can be an effective approach to identifying additional TB 
cases (assuming that the diagnostic test used is of sufficient sensitivity).  If successful in 
identifying cases, systematic screening could also lead to initiating treatment earlier in 
the disease course than passive case detection methods alone.  Given that care-seeking 
delays averaging a year more have been documented globally [14], preventing further 
household and community-level TB transmission by reducing the time between 
symptom onset and treatment initiation through ACF interventions could be important.   
While identification of undiagnosed TB cases among household members is a 
crucial first step, diagnosis without treatment represents a substantial waste of scarce 
TB control resources (while also failing to prevent ongoing TB transmission in the 
community as well as TB-related morbidity and mortality).  Encouragingly, 100% (11/11) 
of household contacts who were diagnosed with TB disease in our study presented to 
health facilities to receive TB treatment within 30 days of their diagnosis.  Though these 
numbers are small, they represent a proof of concept that household-based TB 
diagnoses can be effectively translated into TB treatment initiation under real-world 
conditions.   
Despite the number of household contacts diagnosed with TB and linked to care, 
the relative cost-effectiveness of household contact tracing in rural, high-burden 
settings remains to be seen.  Our results indicate that less expensive diagnostic options 
such as sputum smear microscopy, which cost approximately $2 per test in South Africa 




individual was smear positive in our study, the use of smear microscopy alone, though 
less costly than diagnostic options such as culture or Xpert MTB/RIF, would have 
resulted in our missing over 90% of the active TB cases found among household 
contacts.  Other studies have also reduced expenses and testing burden by performing 
symptom screening to identify the household contacts at highest risk of TB disease [16], 
and therefore most likely to benefit from microbiological testing.  However, had we 
performed even the most general symptom screening (the presence of any cough, fever, 
or night sweats) before performing diagnostic testing, we would have only identified 2 
new (culture positive) TB cases (18% of all true cases), while still testing an additional 
120 individuals without active TB.  While larger studies should be performed to confirm 
this, our findings suggest that symptom screening before diagnostic testing may miss a 
substantial portion of TB cases among household contacts, especially those early in the 
disease course who may be smear negative, but culture positive.  Further analysis of our 
outcome and cost data will help to answer the incremental cost-effectiveness of each of 
these approaches to household contact tracing.  Future research will also explore the 
cost-effectiveness of sensitive diagnostic methods such as Xpert compared to smear 
and/or culture.  Though more research is needed, our results suggest that active case-
finding interventions should be seriously considered in high burden settings, including in 
rural areas, in an effort to control TB.  Our findings are also consistent with the limited 
number of other active case-finding interventions conducted in rural areas [16,17], 
which found high rates of previously undiagnosed TB and HIV, and had good success 




While household contact tracing in this setting found a high prevalence of 
previously undiagnosed TB among household contacts of newly diagnosed TB patients, 
the intervention was not without its challenges.  Transportation infrastructure, including 
roads and household addresses, was limited in many parts of Vhembe District (Limpopo 
Province) where our study took place.  Unpaved roads, of which there were many, 
became nearly impassable during the rainy season, frequently requiring the study team 
to reschedule visits or walk long distances to reach index case homes.  Long distances 
between health facilities and households also presented a challenge, and meant that 
the study team could only visit a small number of homes each day.  Together these 
factors likely contributed substantially to the slow rate of recruitment (Roughly 13 
households visited per month) and relatively higher costs than were observed in the 
Klerksdorp study (data not shown).  These findings are also important for policy makers 
and implementers to consider when setting budgets and planning interventions, and 
may have substantial impact on the reach and cost-effectiveness of contact tracing in 
rural areas.   
In Aim 2 we found that the use of IGRAs in India as a diagnostic for active TB 
disease would be substantially less cost-effective than more appropriate diagnostic 
options such as Xpert MTB/RIF or sputum smear microscopy.  This was due primarily to 
IGRAs poor specificity for active TB in a setting with high background rates of latent TB, 
as the test cannot distinguish between LTBI and active TB disease.  While the WHO does 
not recommend IGRAs as a test for active TB disease, or recommend the use of IGRAs as 




suggests these tests are being used increasingly in countries such as China and India 
[19].  This is especially true in the private sector, where awareness of guidelines for TB 
diagnosis and treatment may be lower, and training/oversight more limited.   
In 2012 India banned the use serological tests for TB, another TB diagnostic that 
was widely—though incorrectly—used in the private sector to diagnose active TB 
disease [20].  Though the ban prevents serological test kits from being imported into 
India, several companies continue to manufacture the tests within India, and evidence 
suggests that the tests are still routinely recommended by private sector healthcare 
providers [21].  Concerns are mounting that IGRAs are also being routinely used by 
private sector providers to diagnose active TB disease, especially among children who 
may have difficulty producing the sputum necessary for tests such as smear microscopy 
or Xpert MTB/RIF.  There is worry that the use of IGRAs have increased in the wake of 
the ban on serological tests in India. 
In addition to raising concerns that IGRAs have filled the void created by bans on 
serological tests for TB, our findings also raise concerns about the quality of TB diagnosis 
and treatment available in the Indian private sector, where 80% of all TB cases receive 
testing and as many as 50% receive treatment for their TB [22].  Our analysis indicates 
that widespread use of IGRAs in India would result in considerable wastage of 
healthcare resources, in addition to negative impacts on the health and safety of TB 
suspects wrongly diagnosed and treated for active TB.  Better guidance and training (as 
well as oversight) may be necessary to ensure proper TB diagnostic and treatment 




continue to be used incorrectly as a test for active TB.  Additional efforts to educate 
practitioners on TB care standards—including the appropriate use of IGRAs in this 
context—should be carried out.   
Our results provide quantitative data to better illustrate the deleterious effects 
of continued use of IGRAs for the diagnosis of active TB in India and other settings with 
high rates of LTBI, and may help bolster outreach and educational efforts to discourage 
off-label IGRA usage.  Providing cost-effectiveness data on IGRA usage may also help to 
highlight the potential human and financial costs of ignoring this issue in India and other 
similar settings. 
For Aim 3 we looked at predictors of IPT completion among a cohort of newly 
diagnosed PLHIV in rural Malawi.  Newly diagnosed individuals were immediately 
screened for TB using a combination of symptom screening and (if TB symptoms were 
present) microbiological testing.  Those individuals with no indication of active TB were 
then screened for IPT eligibility.  Though the cost-effectiveness of this approach has not 
yet been assessed, our findings indicate high levels of acceptability of this approach 
among participants.  The vast majority of IPT-eligible individuals initiated treatment, 
suggesting that the first HIV diagnosis is an ideal time in which to screen for TB and 
assess IPT eligibility.  This strategy is relatively simple to implement, and would be a 
further step towards fully integrating TB and HIV care in high dual-burden settings. 
As IPT initiation rates continue to increase under WHO’s scale up of the “Three Is 




important.  Our study found high treatment adherence among study participants 
initiating IPT soon after their first HIV diagnosis.  Though adherence was based on self-
report, and not direct observation or other objective measurement (and therefore may 
be an over-estimation), these rates were observed when IPT was administered in a 
routine clinical setting.  These conditions are similar to real-world scenarios in which 
individuals are diagnosed with HIV in a clinical setting, assessed for active TB, and (if 
eligible) started on IPT immediately.  Our findings indicate that this may be a feasible 
and effective strategy for providing IPT to newly diagnosed PLHIV.   
Though completion rates differed between older and younger participants, the 
majority of all study participants—regardless of age—received a full course of 
treatment.  While barriers for non-completers should continue to be explored further, 
our findings indicate that a substantial portion of newly diagnosed PLHIV are willing to 
make monthly (or bi-monthly) visits to the clinic to receive preventive therapy for TB.  
Given the clear benefits of IPT for PLHIV, especially those who are newly diagnosed and 
ARV-naïve, clinic-based provision of IPT for newly diagnosed HIV patients should be 
routinely conducted.   
Our research identified several sub-populations that may benefit from additional 
support while receiving IPT to ensure treatment completion.  Younger participants (who 
may be healthier than older participants) had lower rates of completion than older 
participants, and pregnant women and men had lower rates of treatment completion 
than non-pregnant women.   Additional research on the specific barriers faced by these 




interventions to boost completion rates among newly diagnosed PLHIV under 
operational conditions.  By identifying sub-populations at risk for treatment non-
adherence, this research may provide a starting point for future work on IPT initiation 




While TB incidence continues to decline globally, the TB burden in sub-Saharan 
Africa and Southeast Asia remains high.  Ambitious global TB control targets have been 
set as a part of the WHO’s “End TB Strategy”, but if a global TB incidence rate of 
10/100,000 population per year is to be achieved by 2035 new strategies need to be 
deployed in high burden settings.  Research on the cost and potential impact of 
potential TB control interventions, especially as deployed in particular contexts, will be 
vital to inform policy decisions and ensure the efficient deployment of scarce TB control 
resources.  This analysis has evaluated potential interventions that span the TB case-
finding and prevention pathway, from identification of new TB cases to the deployment 
of proper diagnostic tests and identification of factors associated with preventive 
treatment completion in high-risk populations.  Our results have the potential to better 
inform regional and local policy decisions around TB control.  This kind of focused 
operational research is crucial to evidence-based decision-making, and ensuring that the 
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